pioneers
2006/2007 ANNUAL REPORT
it
Un
en
t
&
&
r’s
ct
o
ire
D
Th
RI
CM
Ce
Re
Ce
po
ll
ll
B
rt
Tr
io
an
Pg
lo
gy
sfo
4
Un
rm
at
it
Ce
io
Pg
ll
n
Si
6
U
gn
ni
tP
al
G
lin
g
Em
en
g
10
e
b
U
ry
Th
ni
ol
t
er
Pg
og
ap
M
y
y
12
U
us
Re
ni
cl
se
t
e
ar
Pg
D
ch
ev
14
el
U
op
ni
t
m
Pg
en
tU
16
ni
t
Pg
18
rc
h
id
es
Pr
ea
es
rR
RI
M
tC
ou
Ab
Pg
2
s
er
ar
Be
ts
s
n
or
en
ud
St
ffi
ce
O
f&
ct
ire
D
tio
isa
an
rg
O
af
St
e
Pg
Pg
Pg
Pg
26
24
22
20
{
ce
{
{
Ca
n
Our people
Research
Philosophy
g
in
of
ns
tio
la
Re
&
Fu
Re
nd
se
ra
– ar
isi
A ch
ng
fiv O
e p
Pg
Ba
ye er
la
Fu
34
ar at
nc
nd
i
an on
e
ra
S
al s
he
isi
ys
Re
ng
et
is
ve
Su
–
Pg
Al nu
a
m
fiv
lo e
36
m
ca fr
e
ar
tio om
ye
y
ar
n A
Pg
to ll
an
36
S
al
Re o
ys
se urc
i
s
ar e
ch s &
Pg
20
37
06
/2
00
7
D
Pg
Ho
on
w
at
37
io
Yo
ns
u
Ca
Pg
n
38
He
lp
Pg
44
nd
Fu
ity
m
un
m
Co
ns
io
ns
ne
ct
io
lic
at
Pg
Pg
32
28
Thinking
pioneers
on
Pu
b
lC
ba
lo
G
– F O R
{
ur
{
O
International achievements
C H I L D R E N
E V E R Y W H E R E –
Making it happen
– C H I L D R E N ’ S
M E D I C A L
R E S E A R C H
I N S T I T U T E –
The Children’s Medical Research Institute (CMRI) was founded in 1958 to conduct research into childhood diseases.
The basic philosophy then, as it is now, was that a deeper understanding of disease mechanisms would lead
to better forms of treatment and, in many cases, to the prevention of diseases which cause premature death or
long-term disability.
Over the past 49 years, CMRI has contributed to advances in paediatric health and well-being in many ways,
including the improved survival of premature babies, pioneering microsurgical techniques and developing paediatric
heart and lung support systems for surgery in infants. More recently, the research efforts at the Institute have focussed
on exploring the very basis of human development as a route towards understanding the molecular cause of
disease. We have led the way in gaining new insights into the mechanisms of cancer, in basic studies on the
development of the brain, nerve and muscle cells and their function, in working towards new gene therapies
and in exploring the molecular mechanism for the establishment of the blueprint for embryo development.
One in twenty children is born with a congenital abnormality or chronic condition. If we can determine
the root cause of these problems, it may be possible to either correct or modify their effects.
– – – –
2 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 3
A year of activity 2006/2007
This year saw a major event in the history of the
Children’s Medical Research Institute with the
retirement of Professor Peter Rowe on 24 July 2006.
During his 26 years as CMRI’s Director, Professor Rowe
shaped the Institute into a high-quality organisation
that studies fundamental questions of human biology
and disease. He assembled a first-rate team of scientists
and the equipment and resources needed for their
work. He has left behind an outstanding platform on
which to build for the future. We wish him a very happy
and fulfilling retirement.
The transition to the post-Professor Rowe era has
been smooth, and we greatly appreciate the efforts
of all staff in this regard. In particular, we would like
to highlight the work of two exceptionally talented
staff members, Mr Stephen Ryall (Head of CMRI’s
Administration and Community Relations) and
Mr Greg Craig (CMRI’s Chief Operations Officer).
Stephen worked with Professor Rowe throughout his
26 years with the Institute, and Greg for the majority
of this time. Both have worked very effectively and
with great adaptability to ensure a seamless transition.
Among the many research successes this year,
we would like to single out one for special mention.
This is the discovery by Dr Scott Cohen in CMRI’s
Cancer Research Unit of the molecular components of
an enzyme called telomerase, that 85% of all cancers
depend on for their continuing growth. Although
researchers have known for many years that this is a
critically important feature of cancer cells, no one has
previously been able to obtain sufficient quantities
of this enzyme to analyse it. Dr Cohen devised an
ingenious strategy for extracting telomerase from
cancer cells, and teamed up with members of CMRI’s
mass spectrometry facility to identify its molecular
subunits. This opens the way for the development of
medicines that will treat cancer by blocking telomerase.
This and other research highlights are described within
the pages of this annual report.
Our fundraising has also had an outstanding year.
We particularly appreciate the commitment and hard
work of our committees, who have raised a record
amount this year. Bequests were also at a record high.
Julijana Trifunovic and co-workers produced one of our
best Jeans for Genes campaigns. CMRI’s scientists did
particularly well in competing for grants from funding
agencies such as the National Health and Medical
Research Council of Australia (NHMRC). As a result, we
have been able to fund our research, as well as adding
substantially to CMRI’s endowment fund, which is
critically important to our future.
4 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Throughout the year, we have enjoyed the support
and commitment of CMRI’s Board. We are delighted
that Mr Craig Knowles, former NSW Minister for
Health, has recently become a Board member.
The Board has completed the process of updating
CMRI’s Constitution to bring Board membership
into line with current best practice. A Board working
group led by CMRI Vice-President Mrs Carolyn Forster
negotiated a new agreement with the University
of Sydney, and another working group led by
Mr John Bevins formulated a strategic alliance with
The Children’s Hospital at Westmead (CHW). We look
forward to enhanced interactions with both of these
important institutions, and we also appreciate excellent
cooperative relationships with the other members
of the Westmead Research Hub.
The strategic direction being followed by the
Children’s Medical Research Institute is based on
the understanding that major advances in treatment
and prevention of childhood diseases will come from
discoveries about the fundamental processes of living
cells and what goes wrong in disease. Given the
outstanding resources that have been provided to
us, it now seems to be the right time to redouble our
efforts. Over the coming months, we will be making
a detailed analysis of how we can do this. As we move
forward, your support and encouragement will be
appreciated more than ever.
Frank Martin
President
Roger Reddel
Director
Hub of Activity
– C M R I –
Cell Biology
Cancer Research
– U N I T –
– U N I T –
Telomerase RNA in
immortal cells
Telomerase
interaction
with DNA
Dynamin I inhibitory
drugs for epilepsy
and cancer
Telomerase RNA in
ALT cells
Telomerase and
G-quadruplex
DNA
Telomerase
composition
Dynamin and
endocytosis
Genes and proteins
involved in ALT
Dynamin II and
cytokinesis
IGFBP5
Turning ALT off
Stanniocalcins
Telomere erosion
and DNA damage
signalling
Cell Signalling
Mass
spectrometry
– U N I T –
Prognostic
implications of ALT
YB1 and DNA
damage signalling
Telomere DNA
in ALT cells
p53 and ALT in
glioblastoma
Transgenic/knock-out
mouse technology
Nemaline
myopathy and
therapies
Dynamin II
in cancer
p53 and DNA
damage signalling
p53 blocks
cancer in mice
Fate mapping
– endoderm
Liver-directed
gene therapy
Muscle and
type II diabetes
Rett syndrome and
Mecp2 gene
– U N I T –
Vectors for
haematopoietic
disease/SCID-X1
Williams syndrome
and human behaviour
Mouse models
of muscle disease
Cell Transformation
Craniofacial
development
Gene function in
the endoderm
Immune tolerance
in vaccine development
Stem cell therapy
for muscle disease
(CHW)
Development of Human
Applications Laboratory
(CHW)
Gsc and Dkk1 in
head formation
Eye genetics
Muscle Development
– U N I T –
Gene therapy for
chemoprotection in paediatric
brain tumour treatment
(CHW)
Embryology
– U N I T –
Gene Therapy Research
– U N I T –
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 5
A giant leap
forward
DR COHEN DEVISED AN INGENIOUS
STRATEGY FOR EXTRACTING TELOMERASE
FROM CANCER CELLS.
THIS OUTSTANDING DISCOVERY
Cancer Research
(an international first)
– U N I T –
OPENS THE WAY FOR THE DEVELOPMENT OF MEDICINES
THAT WILL TREAT CANCER BY BLOCKING TELOMERASE.
Telomerase
composition
6 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Working together
– C A N C E R
R E S E A R C H
U N I T
&
C E L L
UNIT HEAD, ROGER REDDEL
What we do
Cancer cells are so similar to our normal cells that it
has been hard to find cancer treatments that leave
healthy cells untouched. The Cancer Research Unit and
Cell Biology Unit are investigating a key characteristic
of cancer cells that distinguishes them from normal
cells – the ability of cancer cells to go on multiplying
an unlimited number of times – they are ‘immortalised’.
If we can find treatments that target this property, they
are likely to have far fewer side effects than currently
available chemotherapies.
Every time normal cells multiply, the telomeres,
the DNA at the ends of the chromosomes, shorten
slightly. Eventually, the telomeres become critically
short, signalling to the cell to stop multiplying.
This is an important built-in barrier against cells
becoming ’immortal’. Cancer cells breach this barrier
by activating a mechanism to prevent telomere
shortening. The majority of cancers do this using an
enzyme called telomerase, which is not present in
most normal cells in the body, and therefore drugs that
block telomerase could provide a specific therapy for
cancer. A minority of cancers use another mechanism
called Alternative Lengthening of Telomeres (ALT).
Drugs to block ALT will be required for these tumours
and for telomerase tumours in the event that they
switch to ALT to evade telomerase blocking drugs.
The Cancer Research and Cell Biology Units are
investigating both telomerase and ALT with the aim
of discovering ways to block these mechanisms and
so directly attack cancer cell immortality.
Cancer Research Unit
Achievements
We have been investigating which genes and proteins
are involved in the ALT mechanism. These analyses
have previously been very time consuming, but Dr WeiQin Jiang and colleagues have now devised a relatively
rapid method and have successfully used it to identify
eight proteins that are likely to be important for ALT.
Cells that use the ALT mechanism are unusual because
they contain a large quantity of telomere fragments
that are no longer attached to chromosome ends.
Dr Clare Fasching, Dr Alessandra Muntoni and their
co-workers have been studying what happens to these
detached telomeres in order to obtain clues as to the
nature of the ALT mechanism itself.
B I O L O G Y
U N I T –
UNIT HEAD, TRACY BRYAN
Does it matter to patients whether their cancers use
ALT or telomerase? We’ve been studying this together
with colleagues in CMRI’s Cell Transformation Unit and
colleagues in Italy, New Zealand and at the Kolling
Institute in Sydney. Patients with one type of cancer,
liposarcomas, do worse if they have ALT. Patients with
the most common form of tumour arising in the brain,
glioblastoma, have a much better life expectancy,
however, if their tumours have ALT. These tumours are
also much more likely to have mutations in the tumour
supressor gene p53. So this is a rare situation in which
the presence of p53 mutations is a favourable indicator.
Highlights
During the past year, we completed a three-year
project to identify the molecular components of
telomerase. Telomerase was first found in human
cancer cells in 1989, and it had become very clear
by 1994 that it was an important feature of most
human cancers. However, despite major efforts in
many laboratories around the world, it had proved
impossible to precisely identify its molecular subunits.
This is because telomerase is present in such tiny
quantities in cancer cells that no one could obtain
sufficient quantities for analysis. Using various indirect
methods, researchers identified 32 proteins that
they thought were molecular subunits of telomerase.
To obtain the definitive answer, Dr Scott Cohen in
CMRI’s Cancer Research Unit enlisted the help of
Dr George Lovrecz, at the CSIRO in Melbourne, to
grow large quantities of cancer cells in a bioreactor.
He also devised an ingenious scheme for extracting
telomerase out of all of the other substances within
cells. Then, with the help of Drs Mark Graham, Nicolai
Bache and Phillip Robinson from CMRI’s Cell Signalling
Unit, he used our mass spectrometry facility to precisely
identify the telomerase subunits. Dr Cohen found that
in fact telomerase has only two protein subunits. We
now know, for the first time, the molecular components
of the enzyme that is critically important for the growth
of 85% of all human cancers.
The future
These are all major steps forward in cancer research.
We intend to capitalise on this progress over the next
year to move closer to the goal of being able to design
anti-cancer treatments based on blocking ALT and
telomerase.
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 7
Telomerase RNA in
immortal cells
Telomerase RNA in
ALT cells
Cancer Research
Telomerase
composition
– U N I T –
Telomere erosion
and DNA damage
signalling
Genes and proteins
involved in ALT
Turning ALT off
Prognostic
implications of ALT
Stanniocalcins
Telomere DNA
in ALT cells
Process
&
Discovery
8 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Telomerase and
G-quadruplex
DNA
OUR EXPERIMENTS WERE MADE POSSIBLE
by a surprising
(AND EXCITING)
chance discovery
OF A REMARKABLY STABLE VARIETY OF
Cell Biology
G-QUADRUPLEX DNA.
– U N I T –
Telomerase
interaction
with DNA
Discovering options
– C A N C E R
R E S E A R C H
Cell Biology Unit
Telomerase is a very specialised and unique enzyme,
and there are many gaps in our knowledge of how
it works. This makes it a fascinating enzyme to study,
revealing the complexity of the machinery inside
cells. It also means that we have much to learn before
we can design rational telomerase inhibitors to treat
cancer. The Cell Biology Unit has been investigating
some fundamental questions about how telomerase
interacts with telomeric DNA.
Highlights and achievements
DNA is normally recognised as the classic double helix
structure; however, the DNA located at telomeres
appears to fold into some unusual structures;
for example, a four-stranded structure known as
a G-quadruplex. It was previously thought that
telomerase is unable to extend G-quadruplexes;
this folding of the telomere was hypothesised to be
one way that the cell controls telomerase action. It
was hoped that this property could be exploited to
develop a class of telomerase inhibitors that ‘lock’
G-quadruplexes in place, thus blocking telomerase
access. Unexpectedly, we found that telomerase is able
to extend a sub class of G-quadruplex structures. This
means that more work is needed to determine which
type of G-quadruplex is present in cells, and whether
the drugs are always able to block telomerase.
Over the last year, we have been further characterising
this unexpected property of telomerase. We found a
mutation of telomerase that made it unable to extend
G-quadruplexes, while its ability to extend ‘linear’ DNA
was unaffected. This indicates that telomerase may
have evolved the ability to deal with these two types
of DNA in a different manner, increasing the chances
that our ‘test-tube’ discovery does reflect the situation
in living cells. The telomerase we have used for these
studies is from a one-celled pond creature called
Tetrahymena. This organism can be easily genetically
manipulated (unlike human cells), so we will be able
to introduce the same telomerase mutation into living
cells. We can then investigate why telomerase would
need to extend G-quadruplexes, and what implications
this has for the ability of cells to multiply.
U N I T
&
C E L L
B I O L O G Y
U N I T –
These experiments were made possible by our
chance discovery of a particularly stable variety of
G-quadruplex DNA. We determined the structure of
this G-quadruplex using the CMRI mass spectrometry
facility; normally this machine is used to identify
proteins, but with the expertise of Drs Mark Graham
and Phillip Robinson of the Cell Signalling Unit, we
were able to adjust the machine to enable it to deal
with DNA molecules.
One of the unique properties of telomerase is its ability
to add multiple ‘blocks’ of DNA to the telomere in
a repetitive manner. It does this using a ‘racheting’
motion, with several parts of the enzyme maintaining
contact with the DNA throughout the process. The
number and location of these DNA ‘anchor sites’ has
been the subject of much investigation, since they
may represent one avenue to block telomerase from
accessing the telomere. In the telomerase field, this
research has been hampered by technical difficulties
in producing large amounts of the enzyme. We have
successfully developed a way to quantitatively measure
the interaction of telomerase and DNA using very
small amounts of enzyme. This has enabled, for the
first time, an evaluation of the relative contributions to
DNA binding of different regions of the enzyme. We
found that there are a minimum of four DNA-binding
sites and that together these enable telomerase to
bind very tightly to telomeric DNA, explaining its
ability to maintain contact with the telomere. Since
our technique is quantitative, we found that a region
previously implicated by others in binding to telomeric
DNA actually contributes only minimally to DNA
binding. Our data also suggest that different DNA
binding sites are used during different stages of the
addition cycle, adding to the complexity of what is
known about telomerase mechanisms.
The future
There is a constant exchange of techniques and
biological insights between the Cell Biology and Cancer
Research Units. The recent exciting work of the Cancer
Research Unit on the identity of the molecular subunits
of telomerase will greatly enhance progress in the Cell
Biology Unit in the coming year.
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 9
Finding the new
– C E L L
UNIT HEAD, ANTONY BRAITHWAITE
T R A N S F O R M A T I O N
U N I T –
OUR RESEARCH WILL BE ENORMOUSLY
HELPFUL FOR PATIENT PROGNOSIS
AND FOR DECIDING UPON THE MOST
EFFECTIVE TREATMENT.
CELLBANK AUSTRALIA
Cultured cells – grown in plastic flasks or dishes outside
the body – are an excellent model for the study of disease
processes because they allow the researcher to focus on a single
cell type. However, cultured cells are vulnerable to contamination
by micro-organisms and other, faster growing cell populations.
Researchers can avoid such contamination by obtaining their cells
from a repository or cell bank. To date, these repositories have been
located outside Australia and can be difficult to access.
CellBank Australia is a new repository which will offer cultured cell
lines to scientists around Australia. These cell lines are collected
from researchers, checked for contamination and made available
to other researchers on a cost recovery basis. Over the last year,
we have completed construction of the facility and worked on its
quality control. The facility is now open for cell line deposits.
The Lady Mary Fairfax CellBank Australia was established by
a joint venture of the Children’s Medical Research Institute,
Cure Cancer Australia Foundation, and the National
Breast Cancer Foundation, and by an Enabling Grant of
the National Health and Medical Research Council.
The facility has been operated by CMRI
since July 2007.
1 0 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
p53 and ALT in
glioblastoma
p53 and DNA
damage signalling
Dynamin II
in cancer
YBI and DNA
damage signalling
p53 blocks
cancer in mice
How p53 works and how p53 receives the signals to
carry out its role in the cell, are the principal areas of
research in the Cell Transformation Unit.
diagnosis. Being able to separate these GBM subtypes
will be useful for patient prognosis and for deciding
upon the best treatment. Our goal is to find ways of
distinguishing these different kinds of GBM. To do this,
we are collaborating with the Cancer Research Unit and
colleagues at the University of Otago, New Zealand
(NZ). We have shown that a mutated P53 gene is able
to distinguish one group of patients with better survival
prospects than those with a normal P53 gene. This is
an unusual finding, as mutated P53 genes are often
found in advanced cancers. Further investigation has
shown that this mutant P53 associates with the ALT
telomere maintenance mechanism, discovered at CMRI
some years ago. ALT has also been previously found to
be associated with better patient prognosis in GBM, a
discovery also made at CMRI with our NZ colleagues.
From our recent findings, therefore, we speculate that
mutant P53 favours the acquisition of ALT and hence
explains why it is associated with better prognosis.
Achievements
Highlights
One currently exciting line of research addresses
the question of how p53 prevents us from getting
cancers. To find this out we have created a genetically
modified mouse in which the P53 gene is altered so
that its protein product is unable to kill cells. We have
investigated whether these mice are susceptible to
cancers, as we know that similar mice with no P53
gene develop lots of cancers. We have found that the
mutant p53 in the cells of this mouse is indeed unable
to cause cell death in response to DNA damage. It also
appears to be unable to temporarily stop cells growing.
However, the mice so far have not developed cancers.
These results indicate that p53 prevents cancers
forming, not by stopping cells growing nor by killing
cells, but by a different process. We will be investigating
this further in the coming year.
In our first full year here at CMRI, we have grown from
a staff of three to our current nine.
What we do
The P53 gene is present in all cells in our bodies and
encodes a protein of the same name, p53. Without
p53 we get cancers.
p53 is produced in extremely small amounts in most
cells; however, if the DNA in these cells becomes
damaged, for example through mistakes in copying
the DNA when a cell divides, exposure to carcinogens,
or by telomere shortening, p53 levels rise. p53 then
does some drastic things to cells – it kills them, stops
them growing temporarily, or stops them growing
permanently. This is called senescence – a cellular aging
process. Many people think that causing one of these
processes to occur, in particular cell death, is how p53
prevents cancers from forming.
We have also focussed on a human brain cancer
called glioblastoma (GBM). Although not common,
GBM is almost always fatal in adults. One problem in
understanding GBMs is that they are not all the same;
groups of patients have different survival times after
The future
A new line of investigation has also commenced
recently in collaboration with the Cell Signalling Unit.
They recently discovered that dynamin II, a protein
required for pinching off little vesicles (bags containing
neurotransmitters) in nerve cells, may carry out a
‘pinching’ role in cell division. Once the chromosomes
of cells have divided, they separate to opposite poles
of the cell and slowly pull away from each other,
eventually breaking off to form two daughter cells.
This process is known as mitosis. Dynamin may
be involved in the final step of mitosis, known as
cytokinesis, clipping apart the two cells like a pair
of scissors. The two Units are working together to
investigate this process, as p53 is a well-known player
in regulating cell division processes.
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 1 1
Leading research
UNIT HEAD, PHILLIP ROBINSON
– C E L L
What we do
The Cell Signalling Unit is unravelling the mechanisms
that underlie two important diseases – epilepsy and
cancer. Cells need to talk to each other and pass
internal messages to carry out their function (for
example growth or cell division). The message is passed
by protein-protein interactions or by proteins modifying
other proteins. We call this cell signalling. Genetic
disease can disrupt the line of communication and so
disrupt the work of a cell. Central to cell signalling is
the protein dynamin. Dynamin I is only found in the
brain, while dynamin II is found in all cells.
Epilepsy is a disease of nerve communication (synaptic
transmission). It affects around 1% of Australians.
Symptoms usually appear during childhood and
seizures may be managed by anti-epileptic drugs.
However, up to 30% of children don’t respond
to currently available drugs. We are investigating
proteins like dynamin I that are required for nerve
communication and which control neuronal excitability.
Cancer is also a disease of defective cell signalling
that allows cells to escape the normal controls that
regulate cell growth and division. We are investigating
proteins like dynamin II to determine their possible role
in cancer.
Highlights
We made discoveries about the molecular machinery
underlying synaptic transmission. Last year, we found
that two main phosphorylation sites in dynamin I
control binding to a partner protein, syndapin. This
year, we mapped the binding site involved in their
interaction and found a further five phosphorylation
sites, suggesting new functions for each of them.
We also mapped every phosphorylation site in the
other major proteins that are involved in synaptic
transmission (synaptojanin, amphiphysin and AP180).
Understanding the role of phosphorylation in these
proteins is important because they are all linked to
sustaining synaptic transmission, which is required for
a seizure to spread.
Our team has also been studying the final stages
of cell division that allow the cells to finally separate
– cytokinesis. We found new proteins involved in the
process and identified that dynamin II is essential for
cytokinesis. The implications are that cancer might
be treated in the future by inhibiting dynamin II
and preventing cancer cells from completing division.
1 2 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
S I G N A L L I N G
U N I T –
Dr Megan Fabbro, who is leading this program,
was awarded the Young Cancer Researcher of the
Year Award from the Cure Cancer Australia Foundation.
In collaboration with scientists at the Royal North Shore
Hospital, we have been studying the protein IGFBP5.
This protein circulates in blood and regulates growth of
various tissues. It is also elevated in some cancers. We
found the phosphorylation sites for this protein and are
endeavouring to better understand its role in cancer.
We also used our mass spectrometry expertise to assist
the Cancer Research Unit in identifying the composition
of the telomerase enzyme.
Major achievements of the year
Blocking dynamin I may lead to new types of antiepileptic drugs while blocking dynamin II may lead
to new anti-cancer drugs. This year, we commenced
a joint program with the National Institute of Health
Anticonvulsant Screening Program in the USA to test
representatives of the best dynamin-blocking drugs we
have developed in conjunction with medicinal chemists
at the University of Newcastle. The outcome will allow
us to establish the principle that dynamin I inhibitors
are a good anti-epileptic target and help define which
drugs should be further developed. We have already
shown that the MiTMAB series of drugs can block
synaptic transmission in a laboratory test.
All current anti-epileptic drugs reduce synaptic
transmission by dampening it down a few percent,
24 hours a day. A dynamin inhibitor acts via a different
mechanism and would represent a potentially new class
of anti-epileptic drug. It should only reduce synaptic
transmission when it is elevated to a very high level;
preventing the build-up to, and spread of, a seizure.
The future
The drug discovery program will be a major focus over
the next 12 months. The outcome of the animal tests of
the anti-epileptic drugs will also determine the potential
for a similar anti-cancer screening program.
Cutting-edge technologies underpin the basic science
beneath all projects within our group and other CMRI
Units and keep us at the forefront of medical science.
The mass spectrometry facility is a prime example
of this and we hope to expand it in the coming year
to boost throughput and sensitivity. The application
of robotics and the new ImageExpress fluorescent
microscope will help with faster assays and screening
of anti-epileptic and anti-cancer drugs.
major advances
in science
Mass
spectrometry
Dynamin II and
cytokinesis
THE FACILITY IS USED EXTENSIVELY
Dynamin I inhibitory
drugs for epilepsy
and cancer
WITHIN CMRI AND IN COLLABORATION
WITH SCIENTISTS AND INDIVIDUALS
Dynamin and
endocytosis
from around
the world
IGFBP5
MASS SPECTROMETRY AND FUNCTIONAL PROTEOMICS FACILITY (MSFPF)
Mass spectrometry is the most rapid and sensitive approach available for protein
identification and characterisation. The MSFPF at CMRI, managed by the Cell Signalling
Unit, currently has two mass spectrometers (MALDI-TOF and quadrupole-TOF). It is a collaborative
research resource that combines applied proteomics with the development of new and improved
methods for protein identification and characterisation. The facility is used extensively within CMRI
and in collaboration with scientists from the Westmead Research Hub and individuals from around
Australia and the world.
This year, the Facility has contributed to major advances in neuroscience, cancer and muscle disease
research. Within the Cell Signalling Unit, we have completed a body of work on the phosphorylation
of all the proteins involved in synaptic vesicle endocytosis. It provided a final crucial step in the
identification of the components of human telomerase made by the Cancer Research Unit of
CMRI. A major collaboration with Professor Kathryn North of The Children’s Hospital at
Westmead has revealed clues to the genetic mechanisms behind two childhood
muscle weakness disorders.
In the next year, the Facility is set to increase its capacity with further
specialist mass spectrometry staff and new instruments.
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 1 3
Exploring development
– E M B R Y O L O G Y
UNIT HEAD, PATRICK TAM
U N I T –
grow and live
a healthy life
UNDERSTANDING THE COMPLEX
PROCESS OF DEVELOPMENT, AS
WELL AS MALFUNCTIONS THAT
CAN RESULT IN SERIOUS
COMPROMISE OF QUALITY OF LIFE
FOR CHILDREN OR THEIR FAMILIES.
Transgenic/knock-out
mouse technology
grow
Fate mapping
– endoderm
grow
Rett syndrome and
Mecp2 gene
Craniofacial
development
Gene function in
the endoderm
Gsc and Dkk1 in
head formation
1 4 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Eye genetics
What we do
The objective of our research program is to understand
the process of normal embryonic development and to
establish how faults leading to birth defects may arise.
We began by tracking the developmental fate of cells
in the early embryo, at a stage well before any visible
body parts can be recognised, a process known as
fate-mapping. The aim was to ascertain if there is a
blueprint – a predetermined arrangement of cells to
generate the various tissues and organs of the embryo.
To do this, we pioneered techniques which involve
tracking the differentiation of marked cells and their
descendants in mouse embryos grown in culture.
Our research has progressed from studying the
formation of the germ layers (the building blocks) to
encompass the stage of organogenesis (the formshaping process). This period of development in the
mouse corresponds to the first eight weeks of human
embryonic life, when any error in development could
result in serious malformations that impact on quality
of life for children and families. We have focussed on
the head, face and jaws, and the eyes.
We also study the developmental basis of Rett
syndrome – a debilitating neurological condition
associated with mutations in the Methyl-CpG-Binding
Protein 2 (MECP2) gene which accounts for up to
10% of all profound intellectual disability in females.
The Eye Genetics Group is seeking genes responsible
for congenital eye defects – cataracts, glaucoma,
anophthalmia (no eyes) and microphthalmia
(small eyes) – in order to find novel treatments for
these conditions.
Highlights and achievements
For over a decade we have systematically examined
the fate maps of different germ layers of the mouse
embryo: starting with the outer layer that generates
the skin and the nervous system (the ectoderm);
followed by the middle layer that produces the muscle,
bone and other supporting tissues (the mesoderm).
Our project reached a major milestone in 2007 with
the near completion of the fate map for the last germ
layer, the inner layer (the endoderm) which forms the
digestive tract.
Our group has identified a set of genes – some of which
were previously unknown – and the components of
signalling pathways that enable cells to communicate
with one another during formation of the gut.
We have developed an expeditious strategy to
determine the function of a gene using mouse
embryonic stem cells in which the activity of a gene
has been altered. With this technique, a whole embryo
can be generated completely from these stem cells
allowing a rapid preliminary study before commencing
the lengthy production and analysis of genetically
modified mouse models. We have already used this
approach to investigate the function of several genes
that are expressed by endoderm cells. Our expertise in
the production of transgenic, knockout and chimeric
mice has also contributed to the work of other Units
within CMRI and external collaborators.
Recently we discovered the interaction of two genes
(Gsc and Dkk1) in head formation – loss of these genes
in mice led dramatically to a loss of the head due to
disruption of a signalling pathway.
Our Eye Genetics Group identified a novel gene in
cataract development. They achieved this by studying
a family with a break in their chromosomes which
helped pinpoint the location of the gene.
Significant progress has been made in the
characterisation of a genetic mouse model for Rett
syndrome. We have identified changes in gene activity
in the brain that reflect the progression of the disease
and accompany the loss of behavioural function.
The future
After the completion of the fate-maps, the next
challenge is to capitalise on our embryological
expertise to visualise the dynamic process of embryonic
development. Digital imaging techniques will be
used to follow the movements of cells, and the
accompanying changes in shape of tissues, as the
embryo develops. This will provide a comprehensive
illustration of how the blueprint is translated into a
whole embryo.
We are building several mouse models with a
mutation in the Twist1 gene for studying the human
condition Saethre-Chotzen Syndrome (SCS), which is
characterised by abnormal skull and facial morphology.
In these mice, the Twist1 gene is specifically switched
off in cranial neural crest cells to determine how loss
of neural crest cells affects craniofacial development
in SCS.
The Eye Genetics Group will identify new disease genes
through clinical investigations and explore several
animal models for genes associated with congenital
eye defects.
We aim to discover therapeutic targets for Rett
syndrome through a collaboration with clinical
geneticists at The Children’s Hospital at Westmead and
a team at the University of Sydney. We will undertake
parallel clinical genetic investigation and animal model
studies of two novel genes that have a potential link to
the Mecp2 gene and may be related to other X-linked
neurological disorders.
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 1 5
Vectors for
haematopoietic
disease/SCID-X1
Liver-directed
gene therapy
Immune tolerance
in vaccine development
Development of Human
Applications Laboratory
(CHW)
Gene therapy for
chemoprotection in paediatric
brain tumour treatment
(CHW)
This is a
tremendously exciting
Gene Therapy Research
– U N I T –
but challenging area
of research.
1 6 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Promising results
– G E N E
T H E R A P Y
R E S E A R C H
U N I T –
UNIT HEAD, IAN ALEXANDER
THE ONGOING CHALLENGE FOR THE GENE THERAPY
RESEARCH UNIT IS TO TAKE OUR MOST PROMISING
LABORATORY RESULTS FORWARD TO HUMAN
CLINICAL APPLICATION. THIS IS NOT A JOURNEY FOR
THE FAINT-HEARTED, AND IS THE CENTRAL MISSION
OF THE UNIT.
What we do
The Gene Therapy Research Unit, a joint initiative with
The Children’s Hospital at Westmead, is focussed on
the development of novel gene-based strategies for
the treatment of genetic conditions affecting children.
This is a tremendously exciting but challenging area
of research requiring both laboratory and clinical
expertise. The liver and bone marrow are two
particularly promising targets for gene therapy, as
many childhood genetic diseases involve these tissues.
The key challenge of gene therapy is to safely repair
or replace faulty genes with healthy ones in a sufficient
number of cells to achieve therapeutic benefit. Our
approach involves the use of cutting-edge gene
delivery technologies (vectors) derived from viruses.
The long but immensely rewarding journey towards
human therapy begins with genetic repair of isolated
cells growing in cell culture using this technology. It
can then progress to the treatment of disease in small
animals such as mice.
Highlights
In the last year, we have successfully treated mice
with two different genetic conditions: X-linked Severe
Combined Immune Deficiency (SCID-X1) by genetic
repair of bone marrow cells; and a urea cycle defect,
Ornithine Transcarbamylase (OTC) deficiency, by
genetic repair of liver cells. The studies on mice with
SCID-X1 are focussed on enhancing the safety of gene
transfer and are part of our ongoing international
collaboration to treat children with this condition with
world leading paediatric hospitals in Paris and London.
Based on the exciting success in mice with OTC
deficiency, we are now also planning to work towards
clinical trials for children with urea cycle defects. This
goal will require substantial effort over a number of
years to be realised. Another extremely promising result
obtained in the last year is the discovery of a strategy
to selectively block unwanted immune responses that
could otherwise interfere with effective gene therapy in
a diverse range of applications.
On the clinical front we are continuing to work
towards a trial aimed at improving the treatment of
children with brain tumours. Our intent is to use gene
transfer to increase the resistance of bone marrow
cells to the damaging effects of chemotherapy. If
successful, this will not only reduce the side effects
of conventional treatment, but also allow higher and
potentially more effective doses of chemotherapy to
be given. This effort, being undertaken in collaboration
with the Oncology Unit in The Children’s Hospital at
Westmead, demands that we successfully confront
complex translational challenges. These include the
commissioning of a specialised human applications
laboratory (HAL), based in The Children’s Hospital at
Westmead, the generation of clinical grade vectors for
gene delivery, the development of assays to monitor
safety and efficacy, and the completion of regulatory
documentation and clinical trial protocols. Our current
aim is to initiate this trial during 2008.
Achievements
While the past year has been particularly productive
and exciting, one particular highlight was the
publication of our research findings in the prestigious
Journal Blood. We showed for the first time that partial
deficiency of the gamma-c gene, which is faulty
in infants with SCID-X1, differentially affects the
development of specialised cells within the immune
system. This finding not only offers insights into the
development of the immune system, but also has
important implications for the improved design of
gene transfer vectors for SCID-X1 gene therapy.
The future
The ongoing challenge for the Gene Therapy Research
Unit is to take our most promising laboratory results
forward to human clinical application. This is not a
journey for the faint-hearted, and is the central mission
of the Unit.
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 1 7
Research for all people
– M U S C L E
D E V E L O P M E N T
U N I T –
UNIT HEAD, EDNA HARDEMAN
Stem cell therapy
for muscle disease
(CHW)
Nemaline
myopathy and
therapies
What we do
The Muscle Development Unit is engaged in a range
of research activities aimed at understanding the
basis for specific muscle diseases, trialling therapies,
characterising novel protein structures that we
discovered in muscle and defining their roles in muscle
disease and type II diabetes. We are also studying how
one gene, discovered in the Unit, Gtf2ird1/MusTRD,
can profoundly affect skeletal muscle and yet also play
a role in the brain. Our approaches span from bench
to bedside.
Human muscle diseases share common features which
can include weakness, repair of damaged muscle cells,
alterations in the size of muscle cells (hypertrophy or
atrophy) and changes in the relative numbers of fasttwitch and slow-twitch muscle cells. In addition, most
of these features of muscle disease are also found in
normal muscle adapting to new usages and can occur
during ageing. Therefore, our findings will benefit not
only individuals who suffer from muscle disease, but
those who suffer muscle or motor neuron damage,
athletes and the normal ageing population.
Highlights
A major focus of our work over the past 10 years has
been to investigate childhood muscle diseases, to
define mechanisms of disease traits and more recently
1 8 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Mouse models
of muscle disease
Williams syndrome
and human behaviour
Muscle and
type II diabetes
to trial therapies. We successfully generated a mouse
model for the major congenital muscle disease,
nemaline myopathy by engineering a mutation in the
α-skeletal actin gene found in human patients. We are
testing potential therapeutic strategies on these mice
alongside trials that are being conducted by Professor
Kathryn North on children at The Children’s Hospital at
Westmead, with very promising results.
Dystrophies are diseases in which muscle is chronically
damaged and repaired because of a defective gene. We
have devised a unique method of providing genetically
corrected muscle stem cells with a selective survival
advantage when introduced into dystrophic muscle.
This is a novel application of a selective cell enrichment
strategy, initially established for haematopoietic cells,
which allows the genetically corrected stem cells
to out-compete diseased stem cells, leading to the
replacement of diseased muscle with normal muscle.
We are collaborating on this with Professor Peter
Gunning and Dr Geoff McCowage of the Oncology
Unit, The Children’s Hospital at Westmead, using tools
generated by the Gene Therapy Research Unit.
We discovered a new protein scaffold in muscle cells
involved in the movement of the GLUT4 molecule that
transports glucose into muscle cells. Defects in glucose
uptake in skeletal muscle are a major contributing
OUR RESEARCH BENEFITS ALL PEOPLE
from the
very young
TO ATHLETES AND THE AGEING
POPULATION.
factor in the development of type II diabetes. In
collaboration with Professor Peter Gunning, The
Children’s Hospital at Westmead, and the Diabetes and
Obesity Research Program at the Garvan Institute, we
are defining the function of this novel protein scaffold
in glucose homeostasis. This potentially provides a
new target for treatment of diseases of altered glucose
clearance, including type II diabetes and obesity.
and behaviour. In early 2007, we were awarded an
NHMRC grant to investigate the role of Gtf2ird1/
MusTRD in aspects of behaviour. We have determined,
using genetically modified mice that are lacking this
gene, that Gtf2ird1/MusTRD plays a role in regulating
sociability and anxieties. We have also found that
controlling Gtf2ird1/MusTRD activity may provide a
means to control seizures.
A number of years ago, we first identified a novel
family of proteins encoded by the gene Gtf2ird1/
MusTRD when looking for proteins that could alter
the composition of fast or slow-twitch muscle cells
in a muscle. We have found that forced expression
of the MusTRD proteins in the muscles of mice can
profoundly change the relative numbers of fast-twitch
and slow-twitch muscle cells and hence, these proteins
may provide a means to alter fibre type composition in
muscles affected by nerve damage and disease.
The future
Achievements
Gtf2ird1/MusTRD lies within a block of genes
commonly deleted in the neurodevelopmental
disorder Williams syndrome (WS). WS is characterised
by specific neurological and cognitive defects with a
unique personality profile. There is much interest in
WS because the neurological and cognitive changes
reveal a genetic basis for aspects of human cognition
The most exciting prospects for the near future are
the therapies that we are developing for nemaline
myopathy and muscle diseases such as the dystrophies.
With our nemaline mouse model, not only are we
close to defining a therapy that can alleviate impaired
mobility, but will also explain the mechanism behind
it. We anticipate that the next stage for the muscle
stem cell therapy will be as a means to improve the
performance of specific muscles in dystrophy patients,
with the goal to improve quality of life. Our close
relationship with The Children’s Hospital at Westmead
will result in the translation of our findings into clinical
trials. The mouse models we have generated allow us
to identify the best potential treatment strategies
for patients.
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 1 9
Grants Advisory Committee
Chairman, P Robinson
Investment and
Finance Committee
Board of Directors
Chairman, R Atfield
President, F Martin
Internal Communications
Committee
Convenor, R Hardman
Audit and Risk
Committee
Chairman, R Atfield
Occupational Health
and Safety Committee
Chairman, K Steiner
Bioservices Management
Committee
Chairman, G Craig
Animal Care and Ethics
Committee
Co-Chairs, P Tam
and I Alexander
Intellectual Property
Committee
Chairman, F Martin
Institutional
Biosafety Committee
Chairman, R Reddel
Scholarships
Committee
Acting Director
R Reddel
Chairman, T Bryan
The organisation
– T H E
2 0 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
C M R I
T E A M –
Jeans for Genes
Executive Committee
Jeans for Genes
Staff
Voluntary
Fundraising
Committees
Administration and
Appeals Staff
National Campaign Manager,
Jeans for Genes
Office Manager
K Ritson
Science Communication
Staff
J Trifunovic
Accounts
Staff
CellBank
Australia Staff
Bioservices Staff
Manager, Administration
and Community Relations
and Company Secretary
Community
Relations Officer
S Ryall
J Philps
Manager, CellBank Australia
A Capes-Davis
Accountant
Manager, Bioservices
J Mullin
I Villaflor
Operations
Staff
Manager, Operations
G Craig
Research Staff
Head, Gene Therapy
Research Unit
I Alexander
Research Staff
Head, Cell
Transformation Unit
A Braithwaite
ICT Staff
Research Staff
Manager, Information and
Communications Technology
D Capes-Davis
Research Staff
Head, Embryology Unit
P Tam
Mass Spectrometry
Facility Manager
V Valova
Head, Cell Signalling Unit
P Robinson
Research Staff
Research Staff
Head, Muscle
Development Unit
E Hardeman
Head, Cell Biology Unit
T Bryan
Head, Cancer
Research Unit
Research Staff
R Reddel
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 2 1
Associate Professor Frank Martin MBBS FRANZCO FRACS AM OPH, President
Frank Martin is Head, Department of Ophthalmology, The Children’s Hospital at Westmead, and
a Visiting Ophthalmologist at the Sydney Eye Hospital. He served on the International Council
of Ophthalmology from 1998 to 2006. He remains a member of the Council of the Asia Pacific
Academy of Ophthalmology and is on the Board of the Lowy Medical Foundation. He is also
Chairman of the Westmead Research Hub Council. Frank has been a CMRI Board member since
1986 and was elected President in April 2000.
Mr John Bevins
Mrs Carolyn Forster OAM, Vice President
Carolyn Forster has been a member of the Canberra Committee of CMRI
since 1973, serving twice as President and twice as Treasurer. She has worked
in the Federal Parliament for eleven years, in the Senate, the House of
Representatives, and the Ministry. She has chaired the ACT Heritage Festival for
eleven years, chaired the Board of Phillip College and was a past President of the
Women’s International Club, ACT. Carolyn is currently President of the Friends
of the National Museum of Australia, President of the Australian Federation
of Friends of Museums, Chair of the Church of St Andrew Conservation and
Restoration Foundation, as well as serving on a number of other committees.
She received an ACT Women’s Award in 1996, a Centenary Medal in 2003,
and an OAM in 2006. Carolyn joined the Board in 1996 and was elected Vice
President in 2000.
Mr Rodney Atfield FIA FIAA FAII, Treasurer
Rodney Atfield was formerly the Managing Director of the Mercantile Mutual (now ING)
group of companies and was Chairman of QBE/Mercantile Mutual Limited. He is an
actuary by profession and is a former President of the Institute of Actuaries of Australia
and has been a Director of a number of industry bodies. He has been involved in task
forces and advisory bodies to Government. Currently he is a Director of HPAL Limited,
Avant Insurance Limited, Hannover Life Re and ING Foundation and is Chairman of
Macquarie University Actuarial Foundation. Rodney’s extensive experience in actuarial
management and financial administration led to his appointment to the Board of the
CMRI in February 2001 and election as Treasurer in December 2001.
Professor Ian Caterson AM MBBS
BSc (Med) PhD FRACP
Ian Caterson is Boden Professor of Human Nutrition
and Head of the School of Molecular and Microbial
Biosciences, University of Sydney. Previously, he
was Senior Staff Specialist and Director of Clinical
Endocrinology at Royal Prince Alfred Hospital. He
was a post-doctoral researcher at the University
of Oxford with Professor Sir Philip Randle FRS. His
research interests have been in insulin resistance
and the causes, prevention and treatment of obesity.
He is a past President of the Australian Diabetes
Society and the Australasian Society for the Study
of Obesity. He is on the management committee
of the International Obesity Task Force and a
regional advisor on Obesity for the World Health
Organisation. He is regional vice-president (AsiaOceania) for the International Association for the
Study of Obesity. Currently he is Co-Chair of the
10th International Congress of Obesity. Ian joined
the Board of the CMRI in 2004.
John Bevins is an advertising copywriter and
Creative Director of independent Australian
advertising agency John Bevins Pty Limited.
He has long been interested in advertising
as a positive social force. His agency was
established in 1982 on work that included
NSW’s highly successful anti-smoking and
Random Breath Testing campaigns, and it
continues to create social marketing and
brand campaigns for clients such as the
Roads and Traffic Authority, Toshiba and
Perpetual. Jeans for Genes was an initiative
of the John Bevins agency, created in a
brainstorm with scientists from the Institute.
In 2001, John was awarded the inaugural
Advertising Federation of Australia (AFA)
medallion for his contribution to the
advertising industry, primarily through his
work as Chairman of the AFA Ethics Working
Party. He has been a member of the CMRI
Board since 1986.
Mr Christopher Cullen AM ED BE FAIM
Christopher Cullen has been a member of the CMRI and the
Board of the Institute since incorporation and was President from
1985 to 1995. He was President of the State, the Australian and
the International Chambers of Commerce successively from 1982
to 2001. From 1992 to 1998 he was Chairman of both Australian
Hearing (the National Acoustic Laboratory) and the NSW Casino
Control Authority. He was formerly the Honorary Treasurer of the
Royal Blind Society and The Children’s Hospital at Westmead. He
was the Chief Executive and a Director of the ACTA Group from
1985 to 1991.
Mr John Dunlop AM
John Dunlop was a member of the Management Committee of
CMRI from 1973 to 1985, serving as President from 1983 to 1985.
As an inaugural member of the Board of the Institute he served as
Honorary Treasurer from 1985 until 1991. He is a Director of the
Hospitals Contribution Fund of Australia Limited and Health Super
Pty Ltd. He was President of The Children’s Hospital at Westmead
from 1983 to 2007 and Managing Director of Edwards Dunlop
and Company Limited between 1978 and 1989.
The Hon Craig Knowles
The Hon Craig Knowles holds a number of advisory roles and directorships in the health, finance, property,
planning and aged care sectors. His roles include: President, Planning Research Centre, Sydney University;
Member of the Advisory Committee, Urban Research Centre, University of Western Sydney; Director, Odyssey
House; Director, Northern Medical Research Foundation; Chairman of Trustees, Casula Powerhouse Arts
Centre Trust Fund; Advisor, Investec Bank (Australia) Ltd and Director, Tulich Family Communities Aged Care.
Craig was a senior Minister in the New South Wales Government for 10 years, serving in the portfolios of
Planning and Housing (1995-1999), Health (1999-2003), Infrastructure, Planning and Natural Resources
(2003-2005) and Minister for Forests and Minister for Lands (2003-2005). He is a Fellow of the Australian
Property Institute and a Certified Practicing Valuer. Craig joined the CMRI Board in May 2007.
2 2 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Directors
Professor Andrew Kemp MBBS PhD FRACP
Andrew Kemp is Professor of Paediatric Allergy in the Department of Allergy, Immunology and Infectious Diseases, The
Children’s Hospital at Westmead. He was Staff Specialist in Clinical Immunology at Flinders Medical Centre, South Australia
and Head of the Department of Immunology at the Royal Alexandra Hospital for Children, Camperdown, 1979-1989. In 1990
he was Director of Clinical Immunology, Director of Paediatric Physician Training and Head of the General Medical Unit at the
Royal Children’s Hospital at Melbourne. He has held appointments as President of the Paediatric Research Society of Australia,
a Councillor of the Australian College of Paediatrics, a Member of the Committee for Examinations of the Royal Australasian
College of Physicians and Chairman of the Written Exam Committee in Paediatrics of the Royal Australasian College of Physicians.
His research interests have included the epidemiological aspects of and immune responses in allergic disease in childhood.
He is an editorial board member of the Journal of Pediatric Allergy and Immunology. He joined the Board of the CMRI in 2003.
Ms Elizabeth Hallett LLB BCom
Professor Kathryn North MD BSc (Med) FRACP
Elizabeth Hallett is a partner in the national law firm,
Deacons. Now based in Sydney, Elizabeth commenced
her career in Melbourne in 1983, worked in Washington
DC in 1989 and was managing partner of Deacons’
Jakarta office from 1992 until 1996. Elizabeth is the
national leader of Deacons’ Corporate and Commercial
Business Unit and her practice focusses on corporate
matters including corporate governance issues and
Corporations Act advice. Elizabeth is also a member of
the Board of Directors of the Australia Indonesia Institute.
Elizabeth was appointed to the Board of Directors of the
Institute in 2001.
Kathryn North is Head of the Neurogenetics Research Unit, Deputy
Head of the Institute for Neuromuscular Research and Associate
Dean of the Clinical School, The Children’s Hospital at Westmead.
She is also the Douglas Burrows Professor and Head of the Discipline
of Paediatrics and Child Health, Faculty of Medicine, University of
Sydney. Following a Postdoctoral Fellowship in Boston she returned
to Australia in 1995 as the recipient of the Children’s Hospital
Research Career Development Award. Her research interests focus
on inherited childhood muscle disorders and neurofibromatosis.
In 2000 she received the Sunderland Award for achievement in
neurobiological research. Kathryn is past Chairman of the Children’s
Hospital Research Laboratories Committee and an Executive Board
member of the World Muscle Society. She is currently a member of
the Children’s Hospital Research Executive and Research Committee,
and the University of Sydney Medical Faculty Advisory Committee.
She is Chairman of the Human Genetics Society of Australasia
Scientific Program Committee and the Genetics Sub-Committee of
the Australian Association of Neurologists. She joined the Board of
the CMRI in 2000.
Mrs Patti Payne OAM MPS PhC
Patti Payne has been a Community Pharmacist
for over 25 years, practicing on the Central
Coast, NSW. She joined the Beecroft Committee
of the CMRI in 1969, serving as President in
1972/1973. In 1991 she was instrumental in
forming the Hills Committee and has been
its President ever since. She is a member of
the CMRI Biosafety Committee and has been
heavily involved with Jeans for Genes since
its inception. She has served on the Board of
Trustees of the Kings School Foundation and has
organised many functions for other institutions
and charities. She is the founding President of
the Women for Pharmacy network, Chairperson
of the Events and Hospitality Committee of the
Federation Internationale Pharmaceutique (FIP)
World Conference, Sydney, 2003 and is the
Australian nominee to the Board of Directors of
the Community Pharmacy Section of FIP. She has
four adult children. A fifth died in infancy from a
genetically related condition. She was awarded
the Medal of the Order of Australia in 2006. Patti
was elected to the Board in October 2000.
Professor Graeme Stewart AM BSc (Med) MBBS PhD FRACP FRCPA
Graeme Stewart was appointed as founding head of Immunology at Westmead
Hospital in 1980. He is the inaugural Director of the Institute for Immunology
and Allergy Research, one of the four founding research groups of the Westmead
Millennium Institute. Graeme was the inaugural President of the Australasian Society
for HIV Medicine and has played a role at a national and international level in HIV
policy, medical education and research. He is a member of the Board of Multiple
Sclerosis Research Australia, Chair of the Clancey Donald Foundation and on the
governing council of the Global Health Institute. His research group focusses on the
genetics of autoimmune disease, particularly multiple sclerosis, HIV and allergies.
He is a past Chairman of the Westmead Medical Staff Council and is Co-Chair of the
NSW Medical Staff Executive Council. He has also been Deputy Chair of the Greater
Metropolitan Clinical Taskforce. He has served on the CMRI Board since 2002.
Dr Roger Reddel BSc (Med) MBBS PhD FRACP, Acting Director CMRI
Roger Reddel heads CMRI’s Cancer Research Unit and is a Senior Principal Research Fellow of the NHMRC and the
Faculty of Medicine, University of Sydney. He obtained a medical degree from the University of Sydney and trained
in medical oncology at the Royal Prince Alfred Hospital. Roger completed a PhD in cancer cell biology at the Ludwig
Institute for Cancer Research, University of Sydney, and received an NHMRC CJ Martin Fellowship and a Fulbright
Fellowship to undertake postdoctoral research at the National Cancer Institute, Bethesda, Maryland, USA. He returned
to Sydney to establish a laboratory with the support of Cancer Council NSW’s Bicentennial Fellowship. Dr Reddel is an
editorial board member of several cancer journals, and served a term as editor of Carcinogenesis. He serves on research
advisory panels, including Cancer Council NSW’s Cancer Research Committee, and is a Director of Cure Cancer
Australia Foundation (CCAF).
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 2 3
CMRI staff
– A N D
S T U D E N T S –
Acting Director
Kelly Morgan Assistant Jeans for Genes
Campaign Manager (Maternity Leave)
BioServices Staff
Lynda Dave BSocSci (SW) Genie/
BioServices Manager
Executive Assistant to the Director
Volunteer Coordinator Jeans for Genes
Bernadeth Gonzaga DVSM,
Margaret La Rosa JP (part-time)
Melissa Nassif Assistant Jeans for
Technical Officer
Acting Deputy Director
Genes Campaign Manager (Maternity
Leave cover)
Carlie Crawford Animal Technician
Roger Reddel BSc (Med) MBBS
PhD FRACP
Patrick PL Tam BSc (Hons) MPhil PhD
EurProBiol CBiol FIBiol
Jan Mullin FPNA MComm
Manager, Administration
and Community Relations
and Company Secretary
Administrative Officer and Accountant
Deepa Desikan Assistant Accountant
Stephen Ryall BHA FFIA
MAUSAE AMAMI
Valeria Souto Accounts Clerk (part-time)
Administration and Appeals Staff
Operations
Kylie Ritson Personal Assistant to the
Greg Craig MPhil (Arch), Grad
Dip Fac Mgt, Grad Dip Opt Mgt
Operations Manager
Manager, Administration and Community
Relations and Office Manager
Denise Schelin, Administrative Assistant/
Karina Picton Animal Attendant
Kerrie McDonald Animal Attendant
Megan Reddel Animal Technician
Mehtap Baserdem Animal Technician
Melissa Jones Animal Technician
Shelley Dimech Animal Technician
Cancer Research Unit
Unit Head Roger Reddel BSc (Med)
MBBS PhD FRACP
Akira Nguyen BMedSc (Hons)
Daphne Wilken Laboratory Assistant
Data Entry Operator (from May 2007)
PhD Student
Donna Cranshaw Personal Assistant
Dianna Maltese Administrative Assistant
Alessandra Muntoni MD MSc PhD
to Operations Manager
Doreen Molasky BSc (Hons) MSc
Laboratory Manager
(from Sept 2006)
Postdoctoral Fellow
Helena West Administration and
Andy Chang BSc (Hons) PhD
Community Relations Assistant
Senior Research Officer
Ella Rizzo Laboratory Assistant
Jodie Mariner Administrative Assistant
Antony Cesare BSc PhD
Janet Moran Laboratory Assistant
Julia Cognet Manager, Special Projects
Mila Tittel BA (Hons) Dip Ed
MAppLing Senior Technical Officer
and Privacy Officer (part-time)
Robert Denne Maintenance Officer
Mary Donnelly Personal Assistant to
Information and Communications
Technology
Director (part-time)
Marjana Curkovic Receptionist
Darryn Capes-Davis BE (Hons)
Sandra Dillon Administrative Assistant/
Data Entry Operator
Manager, Information and
Communications Technology
Vickie Micallef Administrative Assistant/
Data Entry Operator (part-time) (until
May 2007)
Alvin Sebastian BA BLaws,
Dip Bus Programming Information
Systems Officer
Volunteer Assistants
Postdoctoral Fellow
Axel Neumann Dipl Biol Senior
Research Officer, PhD Student
Clare Fasching BSc MSc Judith Hyam
Memorial Scholar, PhD Student (until
March 2007)
Elizabeth Collins BAppSc (Med Lab
Sci) Scientific Administrator
Hilda Pickett BSc PhD Promina
Postdoctoral Research Fellow
Jane Noble BAppSc (BioMed Sc)
MSc (Med) Senior Research Officer
Community Relations and
Science Communication
Bruce Clark, Denva Barber, Diana
Mahony, Helen Pearce, Janet Cooper,
Jennifer Trevarrow, Lesley Brooks,
Linda Facaris, Maria Krikelis, Mark
Pearce, Shirley and David Gibbs,
Val Ryan
(from July 2006)
Jennifer Philps BSc (Hons) Dip Ed
Mass Spectrometry Facility
Jonathan Moore BioMedSci (Hons)
Community Relations Officer
Valentina Valova BSc (Hons) MAppSc
Jane Fleming BSc (Hons) PhD
Manager, Mass Spectrometry Facility
Science Communication Officer
CellBank Australia
Lisa Melton BSc (Hons) PhD Science
Communication Officer (part-time)
Amanda Capes-Davis MBBS PhD
Ruth Hardman BSc Adv, Grad Dip Sci
Comm Science Communication Officer
Elsa Moy BAppSc Research Assistant
(part-time)
Jeans for Genes
George Theodosopoulos BSc
Julijana Trifunovic Dip HSc, MFIA
Research Officer
National Campaign Manager, Jeans
for Genes
Monica Logan BBiomedSc
Artur Gibalka CCNA ICT Assistant
Bill Kotsifas Applications Officer
Edward Zhang Security Officer
2 4 – C M R I
Accounts
Irma Villaflor DVM, MPVM
Manager, CellBank Australia
Research Officer (part-time)
(part-time)
Jennifer Plowman BSc Masters Student
Jeremy Henson BSc (Hons-Biochem;
Maths) MBBS PhD Postdoctoral Fellow
Research Assistant (until Jan 2007)
Kylie Bower BBiotech (Hons) Research
Assistant, Masters Student (Feb 2006)
Lily Huschtscha BSc (Hons) PhD
Senior Research Officer
Lorel Colgin BSc PhD
Senior Research Officer
Nancy Martin BSc MSc Research
Assistant (from July 2006)
Scott Cohen BSc PhD (Chemistry)
Senior Research Officer (until March 2007)
Christine McGee Dip PR MFIA Special
Wei-Qin Jiang BSc MSc PhD Senior
Events Manager Jeans for Genes
Research Officer
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Ying Cao BSc (Med) MMedSc
(Biochem) PhD Postdoctoral Fellow
Michael Lee University of Sydney Summer
Scholarship Student (Dec 2006-Jan 2007)
Andrew White BMedSci (Hons)
MBBS PhD Research Fellow (part-time)
Ze Huai Zhong BSc (Hons) PhD
Nicole Santucci BSc (Hons)
Chris Willcock BSc (Hons) Research
Student (until June 2007), Research
Officer (from June 2007)
Research Assistant
Assistant (until Dec 2006)
Nicole Vlahovich BSc (Hons)
Gene Therapy Research Unit
PhD Student (to March 2007),
Research Officer (to Oct 2007)
Luke St Heaps BSc (Hons) Masters
Student (part-time)
Unit Head Ian Alexander BMedSci
MBBS (Hons) PhD FRACP (Paeds)
HGSA Clinical Geneticist
Marija Mihelec BSc (Hons)
Prathibha Kahatapitiya BSc (Hons)
PhD Student, Australian Postgraduate
Award Scholar
PhD Student
Afroditi Spinoulas BMedSci (Hons)
Renee Szokolai Honours Student
Research Assistant (Maternity Leave)
(March-Nov 2007)
Aiman Jajo Honours student
Stephen Palmer BSc (Hons) PhD
(from Feb 2007)
Senior Research Officer
Allison Dane BSc (Hons)
Embryology Unit
Assistant (from Feb 2007)
Research Assistant
Unit Head Patrick Tam BSc (Hons)
Yongjuan Chen BMed MMed PhD
Christine Smyth MSc PhD Senior
MPhil PhD EurProBiol CBiol FIBiol
Research Assistant
Abidali Mohamedali BSc (Hons)
PhD Student, University of Sydney
Endeavour International Postgraduate
Research Scholar and International
Postgraduate Award Scholar
Sir Norman Gregg Postdoctoral Fellow
(from Jan 2007)
Cindy Kok BSc (Hons) PhD Student
(from March 2007)
Grant Logan BAppSc MSc Senior
Research Assistant
Peter Abraham BSc Honours student,
Macquarie University
Rebecca Storen BMed Sci University
of Sydney/Save Sight Institute Research
Cell Signalling Unit
Unit Head Phillip Robinson BSc
(Hons) PhD
Andrew McGeachie BSc (Hons) PhD
PhD Student
David Loebel BSc (Hons) PhD
Kimberly-Clark Research Fellow
Julie Curtin MBBS (Hons) FRACP
FRCPA PhD Clinical Researcher
Germaine Trusi, University of Applied
Sciences, Mannheim, Germany,
Research Assistant (from Feb 2007)
Visiting Student (Mar-Aug 2007)
Research Assistant (until Feb 2007)
Jerome Laurence MBChB MRCS
Maolin Zheng MSc (Vet) MSc
Senior Research Assistant
Margot Latham BSc Research
Administrator
Samantha Ginn BSc (Hons) PhD Noel
Dowling Research Fellow
Sharon Cunningham BSc (Hons) PhD
Research Officer
Muscle Development Unit
Unit Head Edna Hardeman BSc BA
(Hons) PhD
Postdoctoral Fellow (since July 2006)
Christine Lucas BSc (Hons) PhD
Research Officer (from Feb 2007)
Chandra Malladi BSc BEd MSc PhD
Research Officer
Charlotte Smith BSc (Hons) Research
Assistant (from March 2007)
Jane Seaman Personal Assistant to
Ellen van Dam MSc PhD Research
the Head
Officer (until Aug 2006)
Joshua Studdert BSc (Hons)
George Craft BSc (Hons) PhD Student
Research Assistant
Kirsten Steiner BSc (Hons) MSc
Antonio Lee BSc (Hons) PhD Visiting
Research Assistant
Research Assistant
(to Nov 2006)
Gurdip Hansra BSc (Hons)
Research Assistant
Jane Seaman Personal Assistant to
the Head
Jing Xue BSc MSc PhD Senior Research
Senior Research Officer
Officer (until Sep 2006)
Melinda Power BSc (Hons)
Lingshan Chan BBiomedSc (Hons)
Senior Technical Officer
Research Assistant (from Jan 2007)
Poh-Lynn Khoo BSc (Hons)
Lin Luo BSc (Hons) PhD Student
Senior Technical Officer
Elie Matar University of Sydney Summer
Scholarship Student (Dec 2006-Feb 2007)
Renuka Rao BSc PhD Research Officer
(until Aug 2006)
Emma Kettle BSc MSc
Research Assistant
Sabine Pfister BSc PhD Deutscher
Akademischer Austauschdienst Fellow
Enoch Tay BSc (Hons) PhD
Samara Lewis BSc (Hons) PhD
Research Officer
Jessica Webster Summer Work
Experience Student (Dec 2006 –
Jan 2007)
Jocelyn Widagdo Honours Student (to
Nov 2006) PhD Student (from Feb 2007)
Josephine Joya DVM Research Officer
Kata Popovic Assoc Degree Med Sci
Research Assistant
Mai-Anh Nguyen BSc (Hons)
Postdoctoral Fellow
Megan Fabbro BSc (Hons) PhD
Peter Doherty Fellow
Nancy Sue BMedSc (Hons) PhD
Senior Technical Officer
Research Officer (from March 2007)
Vanessa Franklin BSc (Hons)
Ngoc Chau BChemEng (Hons)
MBiomedEng Research Assistant
Research Assistant
Yvette Jackson BSc Honours Student,
Macquarie University
Sanket Joshi BSc (Biotech)
MBiotech PhD Student (joint with Cell
Eye Genetics Group,
Embryology Unit
Merritt Adams BA PreMed Work
Clinical Geneticist
Maggie Ma BSc Bioinfo (Hons)
Mark Graham BSc (Hons) PhD
Tania Radziewic Biol Tech Cert
Group Leader Robyn Jamieson,
MBBS PhD FRACP, HGSA BMedSci
(from March 2007)
Research Assistant (from Feb 2007)
Research Officer (until March 2007)
PhD Student
Anna Powell BSc (Hons)
Annie Quan BSc (Hons) MComm
Heidi Bildsoe BSc MSc
Anthony Kee BSc (Hons) PhD Senior
Research Officer
Anna Mariana BBiotech Adv (Hons)
Gregory Pelka BBiomedSci (Hons)
PhD Rett Foundation Post-doctoral
Fellow and NHMRC Peter Doherty
Australian Biomedical Fellow
Kenneth Soo BSc (Hons) MBBS
PhD Student, University of Sydney
Medical Foundation Scholar
Agnes Chan Honours Student
Research Officer
Transformation Unit) (from March 2007)
Valentina Valova BSc (Hons) MAppSc
Senior Research Officer,
Mass Spectrometry Facility Manager
Experience Student (Jan-Feb 2007)
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 2 5
Office Bearers
Victor Anggono BSc (Hons)
PhD Student
Patron
Cell Biology Unit
Unit Head Tracy Bryan BSc (Hons) PhD
Amanda Nouwens BSc (Hons) PhD
NHMRC Peter Doherty Postdoctoral Fellow
(to March 2007)
Julie Jurczyluk BSc (Hons)
Her Excellency Professor Marie Bashir
AC, Governor of New South Wales
Acting Director
Roger Reddel BSc (Med) MBBS
PhD FRACP
Research Assistant
Board of Directors
Liana Oganesian BMedSc (Hons)
Andrew Kemp MBBS PhD FRACP
PhD Student (NHMRC Biomedical
Postgraduate Scholarship)
Carolyn Forster OAM, Vice President
Christopher Cullen AM ED BE FAIM
Sharon Finger BSc (Hons) Research
Assistant (to March 2007)
The Hon Craig Knowles
Cell Transformation Unit
Elizabeth Hallett LLB BCom
Unit Head Antony Braithwaite BSc
Frank Martin MBBS FRANZCO FRACS
AM Oph, President
MSc (Hons) PhD
Research Assistant
Graeme Stewart AM BSc (Med) MBBS
PhD FRACP FRCPA
Daniel Speidel Dr. rer. nat. DiplBiochemiker Postdoctoral Fellow
Ian Caterson AM MBBS BSc (Med)
PhD FRACP
(from June 2007)
John Bevins
Hamish Campbell BSc (Hons) PhD
(pending) Postdoctoral Fellow (from
John Dunlop AM
Carina Rubio BSc (Hons)
Kathryn North MD BSc (Med) FRACP
March 2007)
Rodney Atfield FIA FIAA FAII, Treasurer
Priya Ganesan BSc (Hons) PhD
Roger Reddel BSc (Med) MBBS PhD
FRACP Acting Director
Postdoctoral Fellow
Reena Mehta BSc MSc PhD
CMRI/CHW Animal Care and
Ethics Committee (ACEC)
Co-Chairs
Ian Alexander BMedSci MBBS (Hons)
PhD FRACPC (Paeds) CG HGSA Head
Gene Therapy Research Unit, CMRI
Patrick Tam BSc (Hons) MPhil
PhD EuroProBiol CBiol FIBiol Head
Embryology Unit, CMRI
Category A (Veterinarian)
Irma Villaflor DVM MPVM, BioServices
Manager, CMRI
Tanya Stephens BVSc, Honorary
Consulting Veterinarian
Category B (Animal Researcher)
Andy Chang BSc (Hons) PhD Senior
Research Officer, Cancer Research
Unit, CMRI
Samantha Ginn BSc (Hons), PhD
Research Officer, Gene Therapy
Research Unit, CMRI
Tanya Butler PhD Pathology,
Postdoctoral Scientist, Institute for
Neuromuscular Research, CHW
Thomas Fath PhD Biology, Research
Officer, Oncology Research Unit,
CHW
Category C (Animal Welfare)
Patti Payne OAM MPS PhC
Barry Philps BVMSc MRCVS WIRES
Secretary to the Board of Directors
Stephen Ryall BHA FFIA MAUSAE
AMAMI
David Edwards MA FIA FIAA WIRES
Audit and Risk Committee
Category D (Layperson)
Senior Research Officer (from March 2007)
Christopher Cullen AM ED BE FAIM
Denva Barber
Weina Ma BSc (Hons)
Carolyn Forster OAM
Research Assistant
Elizabeth Hallett LLB BCom
CMRI Research Associates
Luciano Dalla-Pozza MBBS FRACP
Frank Martin MBBS FRANZCO FRACS
AM Oph
Margaret Tipper BBus (UWS) GD
Comm Mgt (UTS) AHRI AIMM St
Vincent de Paul Executive
Observer The Children’s Hospital
at Westmead
The Children’s Hospital at Westmead
John Bevins
Peter Gunning BSc (Hons) PhD
Rodney Atfield FIA FIAA FAII Chairman
Karen Brennan MSc
Manager, Transgenic Facility CHW
Investment and Finance Committee
Secretary/Contact Officer
Carolyn Forster OAM
Jane Seaman, CMRI
Christopher Cullen AM ED BE FAIM
Administrative Assistant
Elizabeth Hallett LLB BCom
Donna Cranshaw, CMRI
Research Assistant
Sanket Joshi BSc (Hons) PhD Student
(joint with Cell Signalling Unit)
} This is not a journey for the faint-h
Scott Cohen BSc PhD (Chemistry)
The Children’s Hospital at Westmead
Renu Wadhwa PhD National Institute
of Advanced Industrial Science and
Technology (AIST) Japan
Sunil Kaul PhD National Institute
of Advanced Industrial Science and
Technology (AIST) Japan
Frank Martin MBBS FRANZCO FRACS
AM Oph
Honorary Consulting Veterinarian
Jan Mullin FPNA MComm
Tanya Stephens BVSc
John Bevins
Institutional Biosafety
Committee
Chairman
Rodney Atfield FIA FIAA FAII Chairman
Roger Reddel BBSc (Med) MBBS
PhD FRACP
Roger Reddel BSc (Med) MBBS
PhD FRACP
Secretary
Stephen Ryall BHA FFIA MAUSAE
AMAMI
Jennifer Byrne BSc (Hons) PhD
Carolyn Casey LBB (Minutes Secretary)
Layperson
Patti Payne OAM MPS PhC
2 6 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Scholarships Committee
Biomedical Engineer and
Biological Safety
Jane Noble BAppSc (BioMed Sc)
MSc (Med)
Darren McKinnon B Eng (Mech)
Jennifer Philps BSc (Hons) Dip Ed
Greg Craig MPhil (Arch) Grad Dip
Fac Mgt, Grad Dip Opt Mgt
Julie Jurczyluk BSc (Hons) (from
May 2007)
Leanne Mills BSc (Hons) PhD
Julijana Trifunovic Dip HSc MFIA
Microbiology
Kirsten Steiner BSc (Hons) MSc
(from 2007)
Jeans for Genes Executive
Committee
Lynda Dave BSocSci (SW) (from 2007)
Andrew Cummings, Clorox Australia,
New Zealand and Africa
Elizabeth Deane BSc PhD
(External member)
Molecular Biology/Genetics
Mai Anh Nguyen BSc (Hons)
Alison Kesson MBBS PhD
FRACP FRCPA
Melissa Jones (animal attendant)
John Christodoulou MBBS PhD
FRACP FRCPA
Occupational Health and
Safety Committee
Antony Braithwaite BSc MSc
(Hons) PhD
Phillip Robinson Bsc (Hons) PhD
Tracy Bryan Bsc (Hons) PhD, Chairman
Andrew Glad, Andrew Glad
and Associates
Ruth Hardman BSc Grad Dip Sci
Comm, Chairman
Andrew McKenzie, Impulse
Purchase Specialists
Weini Ma BSc (Hons)
Anita Batho, Torch
Grants Advisory Committee
Brian Moran, Managing Values
Charlie Brown, The Discovery Group
Donna Cranshaw
Antony Braithwaite BSc MSc
(Hons) PhD
Doreen Molasky BSc (Hons) MSc
Antony Kee BSc (Hons) PhD
Enoch Tay BSc (Hons) PhD
David Loebel BSc (Hons) PhD
Grant Logan BAppSc MSc
Julijana Trifunovic Dip HSc MFIA
Greg Craig MPhil (Arch) Grad Dip Fac
Mgt, Grad Dip Opt Mgt
Lisa Melton BSc (Hons) PhD,
Secretary
Gary Williams, Perfection Badges
Irma Villaflor DVM MPVM
Lorel Colgin BSc PhD
John Glover, Pendragon
Jane Noble BAppSc (Biomed Sc) MSc
Megan Fabbro BSc (Hons) PhD
Julie Jurzcyluk BSc (Hons)
Stephen Ryall BHA FFIA MAUSAE
AMAMI
John Coughlin, John Bevins
Pty Limited
Daphne Wilken
Kirsten Steiner BSc (Hons)
MSc Chairman
Liz Collins BAppSc (Med Lab Sc)
Christine Gabiola,
PricewaterhouseCoopers Australia
Felicity Hyde, Feehan
Communications
Jennifer Philps, CMRI
Julijana Trifunovic, Jeans for Genes
Phillip Robinson BSc (Hons) PhD,
Chairman
Kelly Morgan, Jeans for Genes
Leah Daly, Cherry Media
{
hearted. It is an ongoing challenge.
Monica Logan BBiomed Sci
Nancy Sue BMedSc (Hons) PhD
Weini Ma BSc (Hons)
Intellectual Property
Committee
Frank Martin MBBS FRANZCO
FRACS AM Oph, Chairman
Roger Reddel BSc (Med) MBBS PhD
FRACP Acting Director, CMRI
Stephen Ryall BHA FFIA MAUSAE
AMAMI
Member with legal qualifications
nominated by the Board
Elected member of the CMRI Senior
Scientific Staff
Internal Communications
Committee
Afroditi Spinoulas BMedSci (Hons)
Amanda Nouwens BSc (Hons) PhD
Andrew McGeachie BSc (Hons) PhD
Darryn Capes-Davis BE (Hons)
Jane Fleming BSc (Hons) PhD
Mary Cotter, Walkley Foundation
Bioservices Management
Committee
Megan Mair, MOKEM Agency/
Design Lab
Andy Chang BSc (Hons) PhD
(Group Representative)
Morag Burke, Board of Directors
Darryn Capes-Davis BE (Hons)
(Ex Officio Member)
Nigel Turner, Outsource
Marketing Services
Donna Cranshaw (Minutes Secretary)
Norelle Feehan, Feehan
Communications
Edna Hardeman BSc BA (Hons) PhD
(Group Representative)
Ray Simmons, John Bevins Pty Limited
Greg Craig MPhil (Arch) Grad Dip Fac
Mgt, Grad Dip Opt Mgt (Chair
of Committee)
Sally Anne Trigg, Kimberly Clark
Australia Pty Ltd
Gregory Pelka BSc (Hons) PhD
(Group Representative)
Sue Stanbridge, Hotsource.com.au
Pty Ltd
Irma Villaflor DVM MPVM (Ex Officio
Member)
Auditor
Stephen Ryall, CMRI
HLB Mann Judd
Mark Graham BSc (Hons) PhD
(Group Representative)
Solicitors
Patrick Tam BSc (Hons) MPhil PhD
EurProBiol CBiol FIBiol (Ex Officio
Member)
Allens Arthur Robinson (Pro Bono)
Dibbs Abbott Stillman
Priya Ganesan BSc (Hons) PhD
(Group Representative)
Minter Ellison
Sharon Cunningham BSc (Hons)
PhD (Group Representative)
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 2 7
Leading international thinking
– P U B L I C A T I O N S –
PROUDLY CASTING IDEAS TO THE WORLD
Continuous
output
DRIVING RESEARCH AND DEVELOPMENT
COMPETING ON AN
international scale.
Anggono V, Cousin MA & Robinson PJ. Styryl dye-based
synaptic vesicle recycling assay in cultured cerebellar
granule neurons. In Membrane Trafficking, Humana
Press. (Book chapter.) In press.
Anggono V & Robinson PJ. Key Molecules: Dynamin.
In Encyclopedia of Neuroscience, 4th Edn, Elsevier.
(Book chapter.) In press.
Anggono V & Robinson PJ. Syndapin I and endophilin I
bind to overlapping proline-rich regions of dynamin I:
Role in synaptic vesicle endocytosis. J. Neurochem. 102,
931-943, 2007.
Anggono V, Smillie KJ, Graham ME, Valova
VA, Cousin MA & Robinson. PJ Syndapin I is
the phosphorylation-regulated dynamin I partner
in synaptic vesicle endocytosis. Nat. Neurosci. 9,
752-760, 2006.
Bryan TM & Jarstfer MB. Interrogation of G-quadruplexprotein interactions. Methods. In press, 2007.
Butler TL, Au CG, Yang B, Egan JR, Tan YM, Hardeman
EC, North KN, Verkman AS & Winlaw DS. Cardiac
aquaporin expression in humans, rats, and mice.
Am J Physiol Heart Circ Physiol. 2006 Aug; 291(2):
H705-13. Epub 31 Mar 2006.
Cesare AJ & Reddel RR. Alternative lengthening
of telomeres in mammalian cells. In: Nosek J and
Tomáska L (eds) Origin and Evolution of Telomeres,
In press, Landes Biosciences, 2007.
Chen W, Ruell PA, Ghoddusi M, Kee A, Hardeman
EC, Hoffman KM & Thompson MW. Ultrastructural
changes and SR Ca2+ regulation in red vastus muscle
following eccentric exercise in the rat. Exp Physiol.
92: 437-47, 2007.
2 8 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Chen Y-J, Hakin-Smith V, Teo M, Xinarianos GE, Jelinek
DA, Carroll T, McDowell D, MacFarlane MR, Boet
R, Baguley B, Braithwaite AW, Reddel RR & Royd JA.
Association of mutant TP53 with ALT and favorable
prognosis in glioma. Cancer Res. 66: 6473-6476 2006.
Fu Dvan Dam EM, Brymora A, Duggin IG, Robinson
PJ & Roufogalis BD. The small GTPases Rab5 and
RalA regulate intracellular traffic of P-glycoprotein.
Biochimica et Biophysica Acta – Molecular Cell Research.
doi:10.1016/j.bbamcr.2007.03.023, 2007.
Clarke NF, Ilkovski B, Cooper S, Valova VA, Robinson
PJ, Nonaka I, Feng JJ, Marston S & North KN. The
pathogenesis of ACTA1-related congenital fibre type
disproportion. Ann. Neurol. 61, 552-561, 2007.
Ganesan PL, Alexander SL, Watson D, Logan GL, Zhang
DY & Alexander IE. Robust anti-tumor immunity and
memory in Rag-1-deficient mice following adoptive
transfer of cytokine-primed splenocytes and tumor
CD80 expression. Cancer Immunol Immunother. Jun 5;
[Epub ahead of print], 2007.
Cohen SB, Graham ME, Lovrecz GO, Bache N,
Robinson PJ & Reddel RR. Protein composition of
catalytically active human telomerase from immortal
cells. Science 315(5820), 1850-1853, 2007.
Cooper ST, Kizana E, Yates JD, Lo HP, Yang N, Wu
ZH, Alexander IE & North KN. Dystrophinopathy
carrier determination and detection of protein
deficiency in muscular dystrophy using lentiviral
MyoD-forced myogenesis. Neuromuscular Disorders.
17(4):276-284, 2007.
Costa A, Daidone MG, Daprai L, Villa R, Cantù S,
Pilotti S, Mariani L, Gronchi A, Henson JD, Reddel RR
& Zaffaroni N. Expression and clinical relevance of
telomere maintenance mechanisms in liposarcoma.
Cancer Res. 66: 8918-24, 2006.
Crock PA, Bensing S, Smith CJ, Burns C & Robinson PJ.
Pituitary autoantibodies. Curr Opin Endocrinol Diabetes,
13, 344-350, 2006.
Crock PA, Burns C, Bensing S, Smith C & Robinson PJ.
Autoimmune Hypophysitis. In Autoimmune Diseases
in Endocrinology (Book chapter) (Weetman, AP, ed.),
Humana Press. In press.
Domazetovska A, Ilkovski B, Cooper ST, Ghoddusi M,
Hardeman EC, Minamide LS, Gunning PW, Bamburg JR
& North KN. Mechanisms underlying intranuclear rod
formation. Brain 2007. Accepted.
Domazetovska A, Ilkovski B, Kumar B, Valova VA,
Vandebrouck A, Hutchinson DO, Robinson PJ,
Cooper ST, Sparrow JC, Peckham M & North KN.
Intranuclear rod myopathy: molecular pathogenesis and
mechanisms of weakness. Ann. Neurol (Epub Aug 2007).
Fasching CL, Neumann AA, Muntoni A, Yeager TR &
Reddel RR. DNA damage induces ALT-associated PML
Bodies that preferentially associate with linear telomeric
DNA, Cancer Res., In press, June 12, 2007.
Franklin VJ, Bildsoe H & Tam PPL. Fate-mapping
technique: Grafting fluorescent cells into gastrula-stage
mouse embryos at 7-7.5 days post coitum. Cold Spring
Harbor Protocol (In press).
}
Graham ME, Anggono V, Bache N, Larsen MR, Craft
GE & Robinson PJ. The in vivo phosphorylation sites
of rat brain dynamin I. J. Biol. Chem. 10.1074/jbc.
M609713200, 2007.
Graham ME, Kilby DM, Firth SM, Robinson PJ & Baxter
RC. The in vivo phosphorylation and glycosylation of
human insulin-like growth factor binding protein-5.
Mol Cell Proteomics (2007).
Gunning PW, O’Neill G, Hardeman EC. Tropomyosinbased regulation of the actin cytoskeleton in time and
space. Physiological Reviews 2007. Accepted.
Hilliard LM, Osicka TM, Robinson PJ, Nikolic-Paterson
DJ & Comper WD. Characterisation of the urinary
degradation pathway in the isolated perfused rat
kidney. J Lab Clin Med 137, 36-44, 2006.
Jamieson R, Farrar N, Stewart K, Perveen R, Mihelic
M, Carette M, Grigg J, McAvoy JW, Lovicu FJ, Tam
PPL, Scambler P, Lloyd IC, Donnai D & Black GC.
Characterisation of a familial t(16;22) balanced
translocation associated with congenital cataract leads
to identification of a novel gene, TMEM114, expressed
in the lens and disrupted by the translocation.
Human Mutation (In press).
Jiang W-Q, Zhong Z-H, Henson JD & Reddel RR.
Identification of candidate Alternative Lengthening
of Telomeres (ALT) genes by methionine restriction
and RNA interference. Oncogene, Published on-line,
Feb 5, 2007.
Khoo P-L, Franklin VJ, Tam PPL Fate-mapping
technique: Targeted whole embryo electroporation
of DNA constructs into the germ layers of 7-7.5 dpc
mouse embryos. Cold Spring Harbor Protocol (In press).
Kizana E, Chang CY, Cingolani E, Ramirez-Correa GA,
Sekar RB, Abraham MR, Ginn SL, Tung L, Alexander IE
& Marban E. Gene Transfer of Connexin43 Mutants
Attenuates Coupling in Cardiomyocytes: Novel Basis for
Modulation of Cardiac Conduction by Gene Therapy.
Circulation Research. 100(11):1597-1604, 2007.
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 2 9
{
Kizana E, Ginn SL, Smyth C, Boyd A, Thomas SP,
Allen DG, Ross DL & Alexander IE. Fibroblasts modulate
cardiomyocyte excitability: Implications for Cardiac
Gene Therapy. Gene Therapy. 13(22):1611-1615, 2006.
Kozlov SV, Graham ME, Peng C, Chen P, Robinson PJ &
Lavin MF. Involvement of novel autophosphorylation
sites in ATM activation. EMBO J. 25, 3504-3514, 2006.
Kramer BA, Lemckert FA, Alexander IE, Gunning PW &
McCowage GB. Characterisation of a P140K mutant
O6-Methyl-Guanine-Methyl-Transferase (MGMT)
expressing transgenic mouse line with drug selectable
bone marrow. Journal of Gene Medicine. 8(9):10711085, 2006.
Lewis SL & Tam PPL. The definitive endoderm
of the mouse embryo: Formation, cell fates and
morphogenetic function. Developmental Dynamics
235:2315–2329, 2006.
Lewis SL, Khoo P-L, De Young A, Bildsoe H, Wakamiya
M, Behringer RR, Mukhopadhyay M, Westphal H
& Tam PPL. Genetic interaction of Gsc and Dkk1 in
head morphogenesis of the mouse. Mechanisms of
Development 124, 157-165, 2006.
Logan GJ, Wang L, Zheng M, Cunningham SC, Coppel
RL & Alexander IE. AAV vectors encoding malarial
antigens stimulate transgene-specific immunity
but do not protect from parasite infection. Vaccine.
25(6):1014-1022, 2007.
Neumann AA & Reddel RR. Telomerase independent
maintenance of mammalian telomeres. In: T de Lange,
V Lundblad and E Blackburn (eds) Telomeres and
Telomerase. pp. 163-198, Second edition. Cold Spring
Harbor Laboratory Press, 2006.
Odell LR, Quan A, Chau N, Abagyan R, Robinson PJ
& McCluskey A. Virtual screening and validation of a
human dynamin I GTPase domain homology model.
ChemMedChem, 2007.
Oganesian L & Bryan TM. Physiological relevance of
telomeric G-quadruplex formation: a potential drug
target. BioEssays, 29, 155-165, 2007.
Oganesian L, Graham ME, Robinson PJ & Bryan TM.
Telomerase recognises G-quadruplex and linear DNA
as distinct substrates. Biochemistry, In press, 2007.
O’Leary MJ, Xue A, Scarlett CJ, Sevette A, Kee AJ &
Smith RC. Parenteral versus enteral nutrition – effect on
serum cytokines and the hepatic expression of mRNA of
suppressor of cytokine signalling proteins, IGF-I and the
growth hormone receptor in rodent sepsis. Crit Care.
11: R79, 2007 [Epub ahead of print].
3 0 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Palmer SJ, Tay ESE, Santucci N, Bach TTC, Hook J,
Lemckert FA, Jamieson RV, Gunning PW & Hardeman
EC. Expression of Gtf2ird1, the Williams syndromeassociated gene, during mouse development. Gene Expr
Patterns. 2007 Feb;7(4):396-404. Epub 1 Dec 2006.
Pfister S, Steiner KA & Tam PPL. Gene expression
pattern and progression of embryogenesis in the
immediate post-implantation period of mouse
development. Gene Expression Patterns 7(5):
558-573, 2007.
Quan A, McGeachie AB, Keating DJ, van Dam EM,
Rusak J, Chau N, Malladi CS, Chen C, McCluskey A,
Cousin MA & Robinson PJ. MiTMAB is a surface-active
dynamin inhibitor that blocks endocytosis mediated
by dynamin I or dynamin II. Mol. Pharmacol. DOI:
10.1124/mol.107.034207, 2007.
Quinlan GA, Khoo P-L, Wong N, Trainor PA & Tam
PPL. Cell grafting and labelling in postimplantation
mouse embryos. In: Molecular Embryology: Methods
and Protocols (2nd edition). Methods in Molecular
Biology Series (ISBN 9781 5882 94319), Edited by Paul
Sharpe and Ivan Mason, Humana Press Inc., Totowa NJ
(In press).
Reddel RR. A SUMO ligase for ALT [News and Views].
Nature Struct. Mol. Biol., 14: 570-571, 2007.
Robinson PJ. How to fill a synapse. Science 316,
551-553, 2007. (Perspectives.)
Sanoudou D, Corbett MA, Han M, Ghoddusi M,
Nguyen MA, Vlahovich N, Hardeman EC* & Beggs AH*.
Skeletal muscle repair in a mouse model of nemaline
myopathy. Hum Mol Genet. 2006 Sep 1;15(17):260312. Epub 28 Jul 2006. *These laboratories contributed
equally to this study.
Scarr E, Gray L, Keriakous D, Robinson PJ & Dean B.
Increased levels of SNAP-25 and synaptophysin in
the dorsolateral prefrontal cortex in bipolar I disorder.
Bipolar Disord 8, 133-43, 2006.
Shipman KL, Robinson PJ, King BR, Smith R &
Nicholson RC. Identification of a family of DNA-binding
proteins with homology to RNA splicing factors.
Biochem. Cell Biol. 84, 9-19, 2006.
Smyth CM, Ginn SL, Deakin CT, Logan GJ & Alexander
IE. Limiting γc expression differentially affects signaling
via the interleukin (IL)-7 and IL-15 receptors. Blood.
110(1):91-98, 2007.
Tam PPL, Khoo P-L, Lewis SL, Bildsoe H, Wong N,
Tsang TE, Gad JM & Robb L. Sequential allocation and
global pattern of movement of the definitive endoderm
in the mouse embryo during gastrulation. Development
134, 251-260 (Accompanied by a Journal cover
picture), 2007.
Tam PPL, Loebel DAF & Tanaka SS. Mouse gastrulation:
Signalling activities for lineage specification and
embryonic patterning Current Opinion in Genetics
and Development 16: 419-425, 2006.
Tam PPL & Loebel DAF. Gene function in mouse
embryogenesis: Get set for gastrulation. Nature Review
Genetics 8: 368-381, 2007.
Tan TC & Robinson PJ. Mechanisms of calcineurin
inhibitor-induced neurotoxicity. Transplant Rev
(Orlando) 20, 49-60, 2006.
Tarran SL, Thomas G, Markham R, Craft GE, Valova
VA, Robinson PJ, Langlois NE & Vanezis P. The use of
proteomics to study wound healing: a preliminary study
for forensic estimation of wound age. Med.Sci.Law 2007
Apr;47(2):134-40, 2007.
van Dam EM & Robinson PJ. Ral: Mediator of
membrane trafficking. Int. J. Biochem. Cell Biol. 38,
1841-1847, 2006.
Wadhwa R, Takano S, Kaur K, Deocaris CC, PereiraSmith OM, Reddel RR & Kaul SC. Up-regulation of
mortalin/mthsp70/Grp75 contributes to human
carcinogenesis. Int. J. Cancer 118: 2973-80, 2006.
Watson CM, Trainor PA, Radziewic T, Pelka G, Zhou SX,
Parameswaran M, Quinlan GA, Gordon M, Sturm K &
Tam PPL. Application of lacZ transgenic mice to cell
lineage studies In: Molecular Embryology: Methods
and Protocols. Methods in Molecular Biology Series
(ISBN 9781 5882 94319). Edited by Paul Sharpe and
Ivan Mason, Humana Press Inc., Totowa NJ (In press).
Yu Z-Y, McKay K, van Asperen P, Zheng M, Fleming J,
Ginn SL, Kizana E, Latham M, Feneley MP, Kirkland PD,
Lumbers ER & Alexander IE. Lentivirus vector-mediated
gene transfer to the developing bronchiolar airway
epithelium in the fetal lamb. Journal of Gene Medicine.
9(6):429-439, 2007.
Zhang J, Lawrance GA, Chau N, Robinson PJ &
McCluskey A. From Spanish fly to room temperature
ionic liquids (RTILs): Synthesis, thermal stability
and inhibition of dynamin 1 GTPase by a novel
class of RTILs. New Journal of Chemistry. DOI:
10.1039/6707092f 2007.
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 3 1
}
Our global connections
The scientists at the Children’s Medical Research Institute are not working alone. Worldwide, many medical
researchers are working on closely related problems, each one contributing small pieces of the puzzle.
CMRI scientists have established many alliances with colleagues throughout Australia and the world,
frequently working across disciplines, to share expertise and research tools.
The result of this global flow of ideas is a more rapid and accurate trajectory towards a common goal – establishing
the foundation of knowledge that will transform our ability to more effectively treat and prevent disease.
3 2 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Seattle,
Washington,
USA
Bethesda,
Maryland,
USA
Berkeley,
California,
USA
}
Boston,
Massachusetts, USA
Toronto,
Canada
Fort Collins,
Colorado, USA
Americas
San Diego,
USA
Chapel
Hill, North
Carolina, USA
London,
Ontario,
Canada
Houston,
Texas, USA
Hong Kong,
China
Baltimore,
USA
Sydney,
Australia
Seattle,
Washington
USA
Brisbane,
Australia
Iowa City,
Iowa, USA
Melbourne,
Australia
Yale,
USA
Canberra,
Australia
Los Angeles,
California,
USA
Newcastle,
Australia
Australasia/Asia
Perth,
Australia
{
Tsukuba,
Japan
Tokyo,
Japan
Dunedin,
New Zealand
Auckland,
New Zealand
Paris,
France
Milan,
Italy
Lincz,
Austria
Hamburg,
Germany
Cambridge,
UK
Athens,
Greece
Leicester,
UK
Edinburgh,
UK
{
Munich,
Germany
Europe
London,
UK
Odense,
Denmark
Helsinki,
Finland
– C M R I
Heidelberg,
Germany
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 3 3
The endless endeavour
– C O M M U N I T Y
R E L A T I O N S
&
F U N D R A I S I N G –
SINCE OUR INCEPTION
OUR FOUNDATION
HAS BEEN FIRMLY
BUILT UPON THE
Community relations
The Community Relations and Science Communication Group
raises awareness and understanding of the research carried out
at CMRI, supports the fundraising activities of the Institute and
contributes to scientific literacy in schools and the community.
Over the year we spoke at 166 schools and community groups
and held twelve Discovery Days in which community members
learned about genetics, listened to guest speakers and toured
the facility. Over 100 science teachers attended our biannual
Science Teachers Forum, where we provide a professional
development program to complement the HSC Biology syllabus.
CMRI scientists also contribute to these events, with tours,
demonstrations and lectures.
The team represented CMRI at various science exhibitions
including Science in the City at the Australian Museum, Science
EXPOsed at Hyde Park Barracks and the Amazing World of
Science in Canberra. In collaboration with the Australian
Museum we also hosted a successful Science in the Suburbs
event with 57 school students visiting the Institute and a public
seminar in the evening attended by 51 people.
goodwill
OF THE COMMUNITY.
Kimberly-Clark Australia has generously sponsored our new
Discovery Day booklets and a careers booklet for schools
entitled It’s a Scientist’s Life.
The inaugural in-house Science through the Lens science
photography competition was a highlight, generating some
beautiful scientific artwork to be displayed in the Institute and
at Expos. Thank you to Canon, Big Colour, Fronine and Inside
Out Restaurant for their sponsorship. Thanks also to Back to
the Future Education who sponsored a series of four stunning
postcards featuring scientific photographs by CMRI scientists.
The redesigned CMRI website was launched this year making
it a highly useable and current resource for community
members and scientists. Our newsletter Under the Microscope
also continues to provide a wealth of information to keep over
55,000 supporters per quarter informed of progress and events.
A new focus this year has been the formation of the CMRI
Grants Advisory Committee. Science Communication staff are
contributing to this through the identification of philanthropic
Trusts and Foundations whose goals match those of CMRI
scientists. This will provide a targeted approach to generate
much needed funds.
3 4 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Financial management
The surplus available funds this year ($9.93 million), as
has been the custom since our inception, were applied
to the investment trust. This maintains and increases
available income for research in the future, as well as
providing additional funds which will need to be drawn
as the CMRI plans its much needed expansion of research
space and research activities in the near future. Net assets
now stand at over $107 million of which over $94million
is represented by the investment trust. Revenue from the
trust this year represented over 42% of funds available
for research. The balance of research funds came from
successful grant applications at $6.18 million for the year.
Our many supporters
Since our inception in 1958 the CMRI’s
foundations have been firmly built upon the
goodwill and support of the community. It has
been the driving force which has seen the CMRI
emerge as one of the leading, independent
research institutions in this country.
We particularly acknowledge here our core group
of volunteers who help out in the office each
week enabling us to keep our administrative costs
to a minimum. We thank Kimberly-Clark Australia
and The Promina Group who each continue to
support a named Research Fellowship. KimberlyClark Australia has also supported several of the
outreach activities of the Science Communication
Group and Jeans for Genes. We also thank Mrs
Aileen Dowling for the Noel Dowling Memorial
Fellowship and the Judith Hyam Memorial Trust
Fund for Cancer Research whose generosity has
enabled the continuance of two named research
positions and the continued support of Drive for
Charity M4, M5 and Eastern Distributor. Financial
supporters of $1,000 or more and many who
have donated services or goods in kind in the
last financial year are listed later in this report.
Unfortunately, due to space limitations, not all
our generous supporters can be listed.
Jeans for Genes
Now in its thirteenth year Jeans for Genes® continues to raise
significant funds for the CMRI with $4.02 million raised in 2006.
We thank the millions of people who wore their jeans on Jeans
for Genes Day 4 August 2006.
The Jeans for Genes Art Auction was held at the Sofitel Wentworth
Hotel, Sydney on 21 July 2006. Sixteen personally signed jeans
from international celebrities were painted by Australian artists and
auctioned. Hugh Jackman’s jeans painted by Nafisa Naomi sold for
a record breaking $30,000 to John Symond of Aussie Home Loans.
Major sponsors included Vietnam Airlines and The Leading Hotels of
the World.
Jamm for Genes®, a new initiative of Jeans for Genes, was a great
hit, with over 100 venues and bands holding fundraising concerts
throughout Australia. The Do it with Denim® Design Awards, now in
its 2nd year, attracted over 300 entries from young design students
designing garments from old jeans.
In December 2006, the CMRI Board agreed to expand the Jeans for
Genes team. New staff include Christine McGee – Special Events
Manager, Lynda Dave – Genie (Volunteer) Coordinator, and Melissa
Nassif who replaces Kelly Morgan as Jeans for Genes Campaign
Assistant while she is on maternity leave.
In May 2007, two new Jeans for Genes events were held including
the Jeans for Genes Mothers’ Day lunch, organised by the CMRI
Hills Committee with special guest, celebrity chef Kylie Kwong at
The Hilton, Sydney. The inaugural Jeans on the Greens Golf Day was
held at Oatlands Golf Course with corporate supporters and CMRI
suppliers raising over $12,000.
We plan to further expand Jeans for Genes beyond ‘the day’ and
raise funds through new initiatives over the next three years. Once
again we would like to thank our thousands of ‘Genies’ and other
loyal supporters, including the retailers and jeans artists, for their
generosity throughout the year. They are acknowledged elsewhere
in this report.
Fundraising
Gross fundraising results this year amounted to $11.1 million – a record amount due primarily
to a significant increase in funds received in bequests: over $4.8 million this year.
The CMRI continues to be encouraged by the number of generous benefactors who provide
for the CMRI in their wills, all of whom are convinced of the importance of basic research
to secure the health of future generations. For many this conviction has come through the
tragedy of personal experience.
Two large bequests received from Florence Millar and Allan Hayward via our Gerringong and
Northern Beaches Committees respectively, highlighted the importance of our committee
network as ambassadors for CMRI in their local communities. The 35 voluntary fundraising
committees of CMRI are the lifeblood of our community support, this year contributing
over $1.6 million.
The Christmas Catalogue provides an opportunity for fundraising through corporate
Christmas cards, general cards and gifts which can be purchased throughout the year.
It raises a steady income as well as raising awareness of CMRI’s work.
Costs of raising these funds amounted to 24.5 cents in the dollar, a pleasing reduction on
last year and well below the recommended 40 cents under the Charitable Fundraising Act.
A detailed breakdown of all fundraising is shown on page 37.
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 3 5
Funding of research operations
a five year analysis
02/03
03/04
04/05
05/06
06/07
$000’s
$000’s
$000’s
$000’s
$000’s
6223
4480
2175
1
2233
53
15165
7474
6548
2435
–
1527
120
18104
4783
3121
2817
25
1195
124
12065
6931
8248
2871
–
3235
154
21439
8395
10892
2900
–
3283
177
25647
5176
3431
518
1780
34
189
384
180
160
36
50
30
886
313
10079
5086
5719
374
557
1955
25
187
296
213
201
37
41
24
1123
191
10953
7151
6148
419
773
2121
34
173
313
226
333
36
55
47
1122
406
12206
(141)
7388
430
671
2081
20
190
389
213
281
39
63
55
1089
501
13410
8029
7958
484
889
2557
30
157
350
324
206
89
84
102
1101
1382
15713
9934
1721
45
1766
575
1291
1866
990
302
1292
1480
34
1514
Revenue from all sources
Net Proceeds from Fundraising
Investment Income
NH&MRC Grants
Hospital Grants
Other Grants
Other Contributions
TOTAL
Expenditure on research operations
Salaries – Research
Salaries – Animal House
Salaries – Other
Laboratory Supplies
Scientific Books and Journals
Electricity, Gas and Water
Repairs and Maintenance
Research Travel and Conferences
Insurance
Telephones
Postage and Freight
Printing and Stationery
Depreciation
Other Expenses
TOTAL EXPENDITURE
RETAINED FUNDS
Funds Applied to the Acquisition
of Capital
Equipment
Buildings
TOTAL
586
168
754
Balance sheet summary
as at 30 June 2007
Current assets
Non-current assets
TOTAL ASSETS
Current liabilities
Non-current liabilities
TOTAL LIABILITIES
NET ASSETS
05/06
06/07
$000’s
$000’s
5701
96915
102616
4262
106202
110464
4327
191
4518
98098
2817
221
3038
107426
76016
22082
98098
75410
32016
107426
Represented by:
Reserves
Retained funds
TOTAL EQUITY
3 6 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Fundraising
a five year analysis
02/03
03/04
04/05
05/06
06/07
$000’s
$000’s
$000’s
$000’s
$000’s
3556
374
242
453
3341
690
8656
4063
411
267
397
4265
770
10174
4021
467
223
484
1119
1028
7343
3775
277
197
447
3460
1264
9420
4018
403
298
402
4804
1193
11118
1406
240
104
683
2433
6223
1633
210
106
751
2700
7474
1622
241
120
576
2560
4783
1425
124
143
798
2490
6931
1890
105
187
541
2723
8395
Gross proceeds from fundraising
Jeans for Genes
Sale of merchandise
Direct mail
Committees
Bequests
Other
TOTAL
Total costs of fundraising
Jeans for Genes
Sale of merchandise
Direct mail
Other
TOTAL
NET SURPLUS FROM FUNDRAISING
Revenue from all sources &
allocation to research 2006/2007
}
Revenue $25.65m
Net
Donations
$8.40m
Investments
and Assets
$107.43m
Investment
Income
$10.89m
{
$8.40m
$0.18m
Admin, Insurances
and Energy $1.86m
{ }
Depreciation
$1.10m
$6.18m
Other
$0.18m
{ }
Supplies
$3.10m
$9.32m
{ }
{ }
{ }
Salaries
$9.33m
$1.57m
Grants
$6.18m
Travel
$0.32m
Expenditure on Research $15.71m
A detailed set of Audited Accounts is available on request or you can visit our website at www.cmri.com.au to view the full
set of accounts.
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 3 7
Donations
Thank you
– F U N D R A I S I N G –
}
EVERY CONTRIBUTION
HASTENS OUR JOURNEY.
}
}
Committees
Adelaide Committee of CMRI
$833
Beecroft Committee of CMRI
$23,192
Burbs Committee of CMRI
$1,963
Can Can Committee of CMRI
$2,000
Canberra Committee of CMRI
$77,081
Canobolas Committee of CMRI
$10,418
Cessnock Committee of CMRI
$3,050
Gerringong Committee of CMRI
$315,684
Gosford Committee of CMRI
$10,643
Hills Committee of CMRI
$57,769
Kangaroo Valley Committee of CMRI
$11,790
Ku-ring-gai Committee of CMRI
$27,092
Lakkariba Committee of CMRI
$4,145
Lindfield Committee of CMRI
$529
Maroota Committee of CMRI
$21,466
Mudgee Committee of CMRI
$11,206
Northern Beaches Committee of CMRI
$745,696
Port Hacking Committee of CMRI
$50,963
Putney Committee of CMRI
$802
Quirindi Committee of CMRI
$21,736
Racquet Committee of CMRI
$24,357
Springtime Committee of CMRI
$5,485
Strathfield Committee of CMRI
$50,272
Tamworth Committee of CMRI
$14,942
Taree Committee of CMRI
$5,482
Thumbelina Committee of CMRI
$31,084
Vaucluse Committee of CMRI
$26,943
Wagga Wagga Committee of CMRI
$47,263
Wamberal/Terrigal Committee of CMRI
$3,501
TOTAL
$1,607,387
Grants and bequests
Grants
Cancer Council NSW
Cancer Institute NSW
Cure Cancer Australia Foundation
Millipore/Chemicon
National Health and Medical
Research Council
Office for Science and Medical Research
Ophthalmic Research Institute Australia
Rett Syndrome Research Foundation
Wellcome Trust (UK)
TOTAL
Estate of the late
Phyllis Dawn
Ronald Henry John
Lynette Ann
Ruth Winifred
Charlotte Josephine
Muriel Annie
Allan Milton
Eva Elizabeth
Denise Linda
Betty May
Antoinette Hendrika
Howard James Searle
Marjorie Grace
Jean Ellen
Vevienne Therese
Violet Winifred Doro
William Brien
Florence
Christine Winifred
Margarete Anneliese
Elizabeth Jean
Mary Henderson
Simon
Lena May
Sybil Daphne
Janine Haslewood
Bruce
Shirley Babette
Valerie Elaine
Grace Milbro Somers
TOTAL
$509,367
$847,600
$287,500
$23,203
$2,899,548
$1,156,752
$39,958
$79,338
$339,376
$6,182,642
BELLING
$1,318.49
COLBY
$40,000.00
DIGGLEMAN
$2,000.00
FRASER
$200.00
FREELAND
$60,470.89
HAWKINS
$131,240.21
HAYWARD
$661,005.31
HENDERSON
$25,000.00
HIGGINS
$604,362.11
JEFFREY
$46,088.07
JURRIAANS
$5,722.66
LAKE
$3,554.01
LAWN
$150,000.00
LONG
$217,971.77
MANNIX
$1,000.00
MARSH
$10,000.00
MARSH
$1,000.00
MILLAR
$192,000.00
PARFITT
$1,570.00
PRAGER
$272,932.35
RAMSAY
$2,000,000.00
SHORTEN
$2,000.00
STEVENS
$24,501.97
SUTTON
$53,546.55
TICKLE
$110,000.00
TURNER
$7,765.62
WALL
$20,000.00
WHITE
$25,000.00
WILSON
$33,883.47
WOODHOUSE $100,000.00
$4,804,133.48
Supporters of goods and services in kind (Jeans for Genes)
Jeans for Genes Badge and Merchandise Outlets
Babies Galore, Banjo’s, BaySwiss, Best and Less, Big W, Charlie Brown, Crazy Clark, Domayne, Franklins, Gloria Jean’s
Coffees, Glue Store, Go Lo, Harris Scarfe, Harvey Norman, HCF, Independent Jeans Retailers, Jeanswest, Joyce Mayne,
Just Jeans, Lowes, MYER, Participating Pharmacies, Perfume Connection, Pharmacy Guild of Australia, Rebel Sport,
Sizzler, Sunglass Hut, Terry White Chemists, The Warehouse, Toys R Us, Westpac.
Celebrities who donated their jeans
Tina Arena, Layne Beachley, Peter Brock, Smoky Dawson, Megan Gale, Rolf Harris, Natalie Imbruglia, Hugh Jackman,
Nicole Kidman, Elle MacPherson, Dannii Minogue, Greg Norman, Harry Seidler, Steve Waugh, The Wiggles, ACDC
(Angus and Malcolm Young).
3 8 – C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Artists who painted the jeans
Elizabeth Barden, Ben Brown, Robyn Caughlan, Paul Dorin, Garry Fleming, Ernie Gerzabek, Nicholas Huxley, Marlene Jones,
Anwen Keeling, Kathrin Longhurst, Andrew Mangelsdorf, Jos Myers, Nafisa Naomi, Paul Newton, Evert Ploeg, Robyn Ross.
Major supporters
APN Outdoor, ARIA, Arthouse Hotel, Art Studio, Aussie, Austar, Bathers Pavilion, Bel Parco Ristorante, Bernina, Big W, Blue
Sydney, Bondi Surf School, Bottlemart, BMW, Brent Street Studios, BridgeClimb, Burwood Press, Canterbury, Cerrone, Charlie
Brown, Coogee Sands Hotel and Apartments, Decorative Events, Design Lab, Dolphin Watch Jervis Bay, Domayne, Dreamworld,
FitnessFirst, Forty One Restaurant, Harvey Norman, Hawaiian Airlines, Hayman, Huggies, Innoxa, Jeanswest, JetBoating Sydney
Harbour, John Bevins Pty Ltd, Julio Valdes, Kimberly-Clark Australia, Lagoon Restaurant, Langham Hotel Melbourne, Lattouf,
Leading Hotels of the World, Legion Limousines, Lindt of Switzerland, Mad Cortes, Manta, Maxum, Mineral Spa, Minus 5,
MOKEM, MOR, Nova 96.9FM, Pacific Harbour Golf and Country Club, Palazzo Versace, Paper Bark Camp, Penrith White Water,
Peter Lang, Pioneerstudios, Promina, Quest Cronulla Beach, Quest Wollongong, Royal Automobile Club of Australia, Rebel Sport,
Sea World, Shop till you Drop, Sofitel Wentworth, Sunshades Eyewear, Swarovski, Sunglass Hut, Sydney Tower OzTrek, Taylor
Made Travel, The Footy Show, Thomas Gallane Photography, Tomfoolery, Val Morgan, Vibe Hotels, Vietnam Airlines, Western
Plains Zoo, Westfield, Westpac.
Donations and contributions including Jeans for Genes ($1,000 and over)
AMP Foundation
AXA Australia
AAMI
AAMI Insurance
ACOM Professional Pty Ltd
AE Group
AIG
AMP Capital Investors Limited
ANZ Bank – Operations,
Technology & Shared Services
ANZ Consumer Finance
Ablec Electrical Wholesales
Accenture
Adamson, Ross
Agueci, Jennie
Air Road Foundation
Aitken McLachlan Thorpe Lawyers
Albury Wodonga Private Hospital
Alcan Engineering Pty Ltd
Algester Primary School
All Hallows School
All Saints Anglican School
All Saints Grammar School
Allens Arthur Robinson
Allens Arthur Robinson
NSW
VIC
NSW
VIC
NSW
NSW
VIC
NSW
$1,098
$2,999
$3,220
$2,684
$3,054
$1,422
$2,023
$1,098
VIC
VIC
NSW
QLD
NSW
NSW
NSW
NSW
NSW
QLD
QLD
QLD
QLD
NSW
VIC
NSW
$3,416
$2,022
$1,000
$1,799
$2,000
$3,165
$1,437
$1,892
$1,301
$1,066
$1,039
$3,203
$1,000
$1,420
$1,624
$20,137
B & D Australia
B Braun Australia Pty Ltd
BIG W Support Office
BMW Group Australia
BOC Limited
Babcock & Brown Pty Ltd
Bank of Queensland
Bankstown Grammar School
Bankstown Health Service
Barnet, Joan M
Barnsley Public School
Beaconhills Christian College
Belconnen Soccer Club
Belmore Park
Bendigo Bank – Lyric Building
Best & Less Head Office
Bevins, John
Bevis, Jo-Anne
Bio-Rad Laboratories Pty Ltd
Bird, George
NSW
NSW
NSW
VIC
NSW
NSW
QLD
NSW
NSW
NSW
NSW
VIC
ACT
NSW
VIC
NSW
NSW
WA
NSW
QLD
$1,179
$1,192
$137,731
$1,300
$5,966
$1,156
$1,144
$1,639
$2,053
$10,000
$1,116
$1,196
$1,173
$2,878
$4,923
$75,056
$2,000
$7,295
$1,843
$1,158
CA (Pacific) Pty Limited
CAF Community Fund
NSW
NSW
$1,234
$2,204
Amazing Human Body
Ampelite Fibreglass Pty Ltd
Anderson, Neil
Aon Charitable Foundation Pty Ltd
Arden Anglican School
Armstrong, Jan
Armstrong, Nigel
Arthur Phillip High School
Astra Zeneca
Atwell Primary School
Auburn Primary School
Aussie Home Loans
Austar Entertainment
Austar Entertainment Pty Ltd
Austin Hospital
Australia Post OH & S Department
Australian Discount Retail (Trading) Pty Ltd
Australian Federal Police
Australian Hotels Association
Australian Submarine Corporation Pty Ltd
Authentic Trademarks
Avant Insurance
Ave Maria College
Avis Australia
Aviva Australia
NSW
VIC
NSW
VIC
NSW
NSW
NSW
NSW
NSW
WA
VIC
NSW
NSW
QLD
VIC
NSW
NSW
ACT
NSW
SA
NSW
NSW
VIC
NSW
VIC
$2,317
$1,902
$1,000
$5,000
$2,900
$1,200
$1,000
$1,608
$1,034
$1,075
$1,071
$30,000
$3,919
$2,633
$2,090
$1,711
$108,226
$1,308
$1,623
$1,341
$1,035
$2,500
$1,316
$1,531
$1,131
Blacktown City Council
Blacktown RSL
Blacktown Workers Club
Blake Dawson Waldron
Blooms the Chemist, Penrith Plaza
Blue Mountains Grammar School
Boart Longyear Pty Ltd
Bohm, Martin
Boo, Priscilla
Boronia Heights Primary School
Bramble, T and D
Brooklyn Group
Brunsdon AM, Norman K
Bryan, Joan M
Built Environs
Burrows, Valma
Burwood Press
Butler, EG
Butler Primary School
NSW
NSW
NSW
NSW
NSW
NSW
SA
NSW
VIC
VIC
NSW
NSW
NSW
NSW
SA
NSW
NSW
NSW
WA
$1,646
$6,855
$1,303
$1,422
$1,415
$1,072
$1,012
$1,000
$1,552
$1,097
$5,000
$4,177
$2,085
$4,000
$1,551
$1,110
$30,644
$3,000
$1,174
CBI Constructors Pty Ltd
Cadbury Schweppes
– C M R I
NSW
VIC
2 0 0 6 / 2 0 0 7
$2,994
$1,034
A N N U A L
{A
{B
{C
R E P O R T – 3 9
D}
E}
F}
G}
4 0 – C M R I
Camden High School
Canberra Girls’ Grammar School
Canon Australia
Canterbury College – Junior School
Canterbury-Hurlstone Park RSL
Womens Auxiliary
Cardinal Health
Carey Baptist Grammar School
Carlson Wagonlit
Caroline Chisholm Catholic College
Castle Cove Primary School
Castle Hill Public School
Castle Hill Rotaract Club
Catherine McAuley Westmead
Cecchele, Giovanna
Cecil Hills High School
Cement Australia
Centennial Angus Place
Central Coast Area Health Services
Central Coast Creative Craft Group Inc
Centrelink International Services
Centrelink Nowra
Challenger Financial Services Group
Channel 7
Chester Hill RSL & Bowling Club
Co Operative Limited
Children’s Hospital Westmead
NSW
ACT
NSW
QLD
$1,000
$1,685
$1,106
$3,287
NSW
NSW
VIC
NSW
VIC
NSW
NSW
NSW
NSW
WA
NSW
QLD
NSW
NSW
NSW
TAS
NSW
NSW
NSW
$1,000
$1,882
$1,901
$2,500
$1,017
$1,395
$1,262
$1,500
$1,712
$1,080
$1,289
$1,320
$1,200
$1,706
$2,500
$1,502
$1,074
$1,647
$7,800
NSW
NSW
$3,000
$1,331
NSW
$1,000
NSW
NT
ACT
$2,265
$1,120
$1,159
ACT
VIC
$1,976
$1,125
ACT
$1,200
NSW
$1,022
NSW
VIC
NSW
$25,000
$3,264
$1,700
NSW
NSW
NSW
NSW
$2,090
$1,190
$1,004
$20,000
FM Insurance Company Ltd
FSL Systems
Fairfax AO, James
Farrell, John
Federal Court of Australia
Feehan Communications
First Data International
Fishers Stores Consolidated
Flannery’s Pharmacy
Flight Centre Limited
VIC
WA
NSW
NSW
NSW
NSW
NSW
VIC
NSW
QLD
$1,106
$1,897
$70,000
$1,500
$1,321
$1,140
$2,078
$4,360
$1,207
$1,345
Gambier City Pharmacy
Georges River Art Group
Gilgandra Motors Sales & Service
Girraween High School
Gladstone Park Primary School
SA
NSW
NSW
NSW
VIC
$1,087
$2,000
$2,684
$1,192
$1,050
DSC Personnel
Dana Automotive Systems Group
Australia – Yennora
Darwin International Airport
Department of Defence
Department of Finance
and Administration
Department of Human Services
Department of Industry Tourism
& Resources
Department of Infrastructure Planning
and Natural Resource
Earle Page College – University of
New England
Eastern Health – Box Hill Hospital
Eastwood and District Orchid Society
Einfeld Symonds Vince Chartered
Accountants
Elanora Country Club
Elderslie High School
Energy Australia
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Church, Lynne M
Churchlands Senior High School
Circular Quay Railway Station
Civic Hotel
Clare Catholic High School
Clayton Utz (Sydney)
Clayton Utz Foundation
Cleaver, Georgina
Clorox Australia Pty Limited
Coles Supermarket
Coloplast Pty Ltd
Commander Australia Ltd
Commonwealth Bank of Australia
Coorparoo RSL Club
Corbett Research Pty Ltd
Corkhill, William
Cornerstone College
Cornetts IGA Supermarket
Cospak International Pty Ltd
Country Energy
Countrylink Management
Coventrys
Creer Property
Croll, Judith
Crown Scientific Pty Ltd
Cummins Engine Co
NSW
WA
NSW
NSW
NSW
NSW
NSW
NSW
NSW
SA
VIC
NSW
NSW
QLD
NSW
NSW
SA
QLD
NSW
NSW
NSW
WA
NSW
NSW
NSW
VIC
$10,000
$1,227
$6,740
$1,251
$1,139
$2,576
$4,661
$1,025
$12,669
$1,139
$2,078
$1,536
$1,106
$3,746
$29,500
$5,000
$1,060
$1,753
$2,497
$1,542
$2,424
$1,455
$3,349
$1,000
$1,275
$8,364
ACT
NSW
QLD
NSW
NSW
QLD
NSW
$1,968
$1,000
$1,000
$6,589
$50,000
$1,007
$1,060
NSW
QLD
NSW
$117,349
$1,300
$5,533
Energy Australia Employees
Children’s Appeal
Enertrade
Epping Railway Station
Ernest & Piroska Major Foundation
Eventide Homes (NSW)
Everyday Hero Pty Ltd
Excelsior Public School
NSW
QLD
NSW
NSW
NSW
QLD
NSW
$3,000
$1,019
$1,408
$42,858
$20,000
$2,069
$1,001
Foodland Superfresh Bordertown
Forster, Carolyn
Franklins Support Office
Frankston High School
Fraser, Jeannie Ross
Fred Hosking Pty Ltd
Frederick Irwin Anglican School
Freedman, Clarette
Freeman Catholic College
French, Rae
SA
ACT
NSW
VIC
NSW
NSW
WA
NSW
NSW
NSW
$1,025
$1,272
$50,000
$1,253
$1,000
$4,009
$2,300
$1,000
$1,586
$15,000
VIC
VIC
$1,200
$1,023
NSW
NSW
$2,000
$2,825
Department of the Environment
& Water Resources
Devereaux, Maureen
Discount Jeans
Donovan, Tricia
Dowling, Aileen
Downlands College
Doyle, F P
Drive for Charity – M4, M5
and Eastern Distributor
Duffie, Mark
Dunlop, Ian
Gladstone Park Secondary College
Glaxo Smith Kline
Glendonbrook Wines & Daly Smith
Corporation
Gloria Jean’s Coffees Head Office
Gold Creek Primary School
ACT
Gollan, Judith
NSW
Goodwill Charity Card Shop
NSW
Gordon Institute of TAFE
VIC
Gordon Railway Station
NSW
Goulburn Valley Grammar School
VIC
Goulburn Valley Health – Children’s Ward VIC
$1,564
$2,000
$20,109
$1,196
$2,192
$1,268
$1,200
Governor Philip King Public School
Grant Thornton
Green, JH
Gregory, Hal & Diana
Guildford Grammar School
Guildford Leagues Club
NSW
QLD
NSW
NSW
WA
NSW
$1,457
$1,864
$1,100
$10,217
$2,116
$1,651
HCF Head Office
HSBC Bank Australia Ltd
Haileybury College
Hale, Alison
Hale, Jean
Hall, Anthony
Hannan, Kieren
Hansford, Richard
Hare and Forbes Machinery House
Harris Scarfe Australia Pty Ltd H/O
Harristown State High School
Harwood Andrews Lawyers
Hatch, BC
Hatch Associates Pty Ltd
Hawkesbury High School
NSW
NSW
VIC
NSW
NSW
QLD
NSW
NSW
NSW
SA
QLD
VIC
NSW
WA
NSW
$12,508
$2,217
$1,742
$5,065
$6,045
$18,350
$1,361
$4,831
$5,000
$8,663
$1,032
$1,107
$2,000
$1,158
$1,663
Heath, AE
Heidelberg Graphic Equipment
Hicks, Ian & Lea
Hind, David & Jo
Hodgkinson & McInnes Pappas
Hornsby Girls High School
Hornsby Railway Station
Hotsource
Howchin, Jean
Howell, Donna
Hume Building Society
Hunter Hall Charitable Giving Program
Hunter Valley Grammar School
Hurstville Public School
Hutton, DG
NSW
VIC
NSW
NSW
NSW
NSW
NSW
NSW
NSW
NSW
NSW
NSW
NSW
NSW
NSW
$1,000
$1,000
$10,580
$4,000
$1,195
$2,270
$1,640
$1,684
$10,000
$1,266
$1,372
$35,927
$1,260
$1,640
$1,000
IVECO Trucks
Ian McNair Charitable Foundation Ltd
Ignatius Park College
Ingleburn RSL Club
Ivanhoe Grammar School –
The Ridgeway Secondary
J P Morgan
Jadin Chemist Group – Big Box Chemist
James Hardie Building – Social Club
James Ruse Agricultural High School
Jazz in the Junction
Jeans West – Head Office
Jenkins, Alan
VIC
NSW
QLD
NSW
$1,134
$2,000
$1,172
$1,574
NSW
NSW
QLD
NSW
$1,000
$2,691
$3,084
$2,400
VIC
NSW
QLD
NSW
NSW
QLD
VIC
ACT
$1,033
$3,012
$1,449
$3,114
$1,247
$25,044
$45,741
$2,000
Jennings, Valda P
John Bevins Pty Limited
John Paul College
John Sample Group Pty Ltd
John Wollaston Anglican
Community School
Jolly & Family, Alan & Ann
Jones, Oliver & Paula
Jones, Wayne
Jordan, GV
Judith Hyam Memorial Trust Fund
for Cancer Research
Just Jeans Head Office
WA
NSW
USA
NSW
NSW
$1,171
$3,000
$2,569
$1,100
$1,500
NSW
VIC
$154,106
$68,141
KPMG
K-Mart
KCA Warwick Farm Social Club
Keeghan, Gerard
Kellerman, GM
Kengreen Consulting Pty Ltd
Quantity Surveyors
Kilikanoon Clare Valley
Kimberley Park Primary School
NSW
VIC
NSW
VIC
NSW
$3,147
$1,331
$1,600
$2,000
$3,000
NSW
NSW
QLD
$4,355
$2,500
$1,179
Lalor Secondary College
Lane Cove Public School
Le Page Primary School
Leighton Holdings Pty Limited
Lions Club of Oatley
Liverpool City Council
Locker Room – Telstra Dome
VIC
NSW
VIC
NSW
NSW
NSW
VIC
$1,034
$1,237
$1,034
$6,796
$1,520
$1,000
$1,855
MFR Financial Planners Australia Pty Ltd
MLC School
MYER Community Fund
Mackisack, Joan
Macquarie Bank Foundation
Macquarie Bank Ltd –
Banking & Securities Division
Macquarie Financial Services Group
Maitland Grossmann High School
VIC
NSW
VIC
NSW
NSW
$1,115
$2,117
$78,377
$4,584
$1,244
NSW
NSW
NSW
$1,000
$1,351
$1,662
Kimberly-Clark Australia Pty Ltd
Kimberly-Clark Australia Pty Ltd
Kincoppal-Rose Bay School of
the Sacred Heart
Kingsford Hotel
Kinross Wolaroi Primary School
Knox Grammar School
Kolak, Nada
Krispy Kreme
NSW
SA
$64,982
$2,073
NSW
SA
NSW
NSW
NSW
NSW
$1,160
$1,003
$1,140
$2,000
$3,740
$1,682
Locksmiths Supply Company
Lowe, Michael
Lowes Manhattan Head Office
Lubrizol International Inc
Lumley General Insurance Ltd
Lycopodium Engineering Pty Ltd
VIC
NSW
NSW
NSW
NSW
WA
$2,156
$2,000
$21,413
$1,090
$1,976
$11,016
Man Investment Australia Ltd
Maranatha Christian College
March, Rhonda
Marion McCosker
Martin Place
Marymount Primary School
Mater Mothers Hospital
McAdams, Ian
McCarthy Catholic College
NSW
WA
NSW
NSW
NSW
QLD
QLD
NSW
NSW
$4,295
$1,038
$2,470
$2,500
$8,605
$1,103
$1,380
$5,000
$1,302
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
{H
{ I
J
{K
{L
{M
R E P O R T – 4 1
N}
O}
P}
Q
}
R
S}
4 2 – C M R I
McKernan, Judith
McKinnon Direct
Medicare Australia
Medicare Australia
Medicare Australia Social Club
Medtronic Australasia Pty Ltd
Melbourne East Group Training
Melbourne Girls Grammar
Merrill Lynch
Metricon Homes Qld Pty Ltd
Metropolitan Ambulance Service
NSW
NSW
WA
NSW
NSW
NSW
VIC
VIC
NSW
QLD
VIC
$1,000
$8,900
$2,703
$4,819
$1,484
$1,007
$1,598
$1,889
$5,305
$1,087
$3,535
Millard, Anita
Minter Ellison Lawyers
Monckton, EM
Montgrove College
Mortgage Choice
Morton, Patricia
Motors Pty Ltd
Mount Eliza North Primary School
Mowbray College
Munno Para Foodland
Musashi Pty Ltd
NSW
NSW
NSW
NSW
NSW
NSW
TAS
VIC
VIC
SA
VIC
$1,000
$1,382
$1,000
$1,500
$1,538
$1,026
$1,200
$1,069
$1,952
$1,049
$1,247
NSW Business Chamber
NSW Businesslink
NSW Teachers Credit Union
Nagle College
Narangba Valley State High School
Narellan Vale Public School
Needs, K & L
Nell & Hermon Slade Trust
Nepean Hospital Volunteers Gift Shop
Neuhaus, Gillian C
Neutral Bay Public School
NSW
NSW
NSW
VIC
QLD
NSW
NSW
NSW
NSW
NSW
NSW
$1,601
$1,327
$2,568
$1,378
$1,056
$1,638
$1,072
$1,000
$1,255
$4,000
$1,287
Newington College
News Ltd
Niagara Park Public School
Noosaville State School
North Bondi RSL
Northline
Note Printing Australia –
Occupational Health Centre
Nuplex Industries (Aust) Pty Ltd
Nutricia Australia Pty Ltd
NSW
NSW
NSW
QLD
NSW
NSW
$2,157
$1,882
$1,453
$1,099
$1,519
$1,798
VIC
NSW
NSW
$1,396
$1,586
$1,305
O’Connor, Kevin & Betty
O’Neill, Helen
Oatlands Golf Club Associates
Office of Fair Trading
Office of State Revenue –
State Department Recovery
NSW
NSW
NSW
NSW
$1,600
$1,000
$4,360
$2,718
VIC
$15,000
NSW
$3,561
Olympic Hotel
Open Training & Education Network –
Social Committee
Orange High School
Ord Minnett Group Limited
Orme, WJ and EN
NSW
NSW
NSW
NSW
$1,480
$1,056
$10,725
$5,000
Pacific Brands Hosiery Group
Parramatta City Council
Parramatta Leagues Club
Pasadena Foodland
Pendragon
Penleigh & Essendon Grammar School
Penrhos College
Penrith Anglican College
Perfection Badges
Perpetual Trustees Australia Limited
Peter Sheahan Pty Ltd
Peters, Russell
Pfizer Australia Pty Ltd
VIC
NSW
NSW
SA
NSW
VIC
WA
NSW
NSW
NSW
NSW
VIC
NSW
$1,413
$2,241
$1,419
$1,010
$24,047
$2,904
$1,445
$1,325
$6,720
$1,500
$1,000
$1,000
$2,112
Philps, Jennifer
Picton High School
Pitt Street Mall
Pittwater High School
Pittwater RSL
Powerlink Queensland
Prairiewood High School
Presbyterian Ladies’ College, Sydney
Preston Group
Promina Group Limited
Public Trustee
Pymble Ladies College
NSW
NSW
NSW
NSW
NSW
QLD
NSW
NSW
NSW
NSW
NSW
NSW
$2,031
$1,128
$4,266
$1,033
$2,780
$1,579
$1,054
$1,100
$21,370
$151,271
$1,527
$1,947
QBE Insurance Group Limited
Queen Victoria Building
Quakers Hill High School
R F Entertainment & Promotions
R K Thomas Pty Ltd
RAAF School of Technical Training
– Navy Admin
Rabobank
Rail Corporation
Ramsden, Elizabeth
Ravenswood School for Girls
Ray White Double Bay Group
Raytheon Australia Pty Ltd
Rebel Sport Head Office
Reddel, JD
NSW
NSW
NSW
NSW
QLD
$15,000
$2,171
$1,449
$1,000
$2,396
NSW
NSW
NSW
NSW
NSW
NSW
QLD
NSW
NSW
$1,000
$1,699
$2,973
$8,000
$5,444
$2,000
$1,371
$10,197
$15,000
Redlands Preparatory School
Regional Breakthroughs
River Gum Primary School
Riverside Girls High School
Robinson, Ian
Roche Diagnostics Pty Ltd
Rotary Club of Parkes
Rotary Club of Turramurra
Roxburgh, Roy
Royal Automobile Club of Australia
Royal Darwin Hospital
Royal Oak Hotel
Ryde Secondary College
Ryde-Eastwood Leagues Club
NSW
SA
VIC
NSW
NSW
NSW
NSW
NSW
NSW
NSW
NT
VIC
NSW
NSW
$1,518
$1,900
$1,057
$1,016
$1,650
$1,140
$6,000
$1,234
$1,000
$8,323
$1,099
$1,440
$1,083
$1,804
SCEGGS Darlinghurst
Saha International
Salmon, JH & D
Samies Girl
NSW
VIC
NSW
QLD
$1,033
$1,708
$1,000
$1,095
Sanders Jannali First National Real Estate
Scotch College Adelaide
Scott Motor Group
Servite College
NSW
SA
NSW
WA
$1,280
$1,451
$1,090
$1,460
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T –
Seven Hills Toongabbie RSL Club
Seven Network
Sheriff’s Office
Sizzler Head Office
Skevington, Clement
Skinner, Eric
Slack, Judith
Smith, Alan & Jennifer
Souter, Shirley M
South East Queensland Water
Specialist Dental Suite
Spotless Services Limited
Spruson & Ferguson
St Angela’s Primary Catholic School
St Charbel’s College
St George School
St Helena Secondary School
St Ives Real Estate
St James Station and Hyde Park
St John’s Primary School
St Joseph’s College
St Joseph’s College
St Lucia News
St Luke’s Anglican School
St Madeleine’s Catholic Primary School
St Mark’s Primary School
NSW
NSW
NSW
QLD
NSW
NSW
NSW
NSW
NSW
QLD
NSW
VIC
NSW
NSW
NSW
NSW
VIC
NSW
NSW
NSW
VIC
NSW
QLD
QLD
NSW
NSW
$1,447
$3,000
$1,000
$3,112
$4,300
$1,560
$2,200
$5,063
$1,000
$1,448
$1,912
$1,026
$2,500
$1,341
$3,397
$1,000
$1,073
$1,693
$5,356
$1,111
$1,217
$1,611
$1,715
$1,220
$1,177
$1,083
Tara Anglican School For Girls
Taree High School
Target
Tattersall, Edna
TechFlare Solutions
Tenix Group
The Chef’s Toolbox
The Good Guys
The Hills Grammar School
The J & G and JB Bedwell Foundations
The Kings School
The Knox School
The McGrath Motor Group
The Moore Family Philanthropic
Foundation Limited
The Perfume Connection
The Public Trustee of QLD
The RA Gale Foundation
The Riviera Group
The Tweed Heads Hospital
NSW
NSW
NSW
NSW
NSW
NSW
NSW
WA
NSW
NSW
NSW
VIC
NSW
$1,026
$4,118
$1,020
$2,500
$2,200
$1,472
$2,966
$1,090
$2,449
$13,382
$1,466
$1,164
$2,954
NSW
QLD
QLD
NSW
QLD
NSW
$2,000
$4,472
$1,599
$6,000
$1,359
$1,127
UFS Dispensary
UBS
University of Western Sydney –
UWS Connect
VIC
NSW
$1,520
$1,450
NSW
$1,220
Wattyl Australia Pty Limited
Wellington Primary School
Westfield Design & Construction
Pty Limited
Westfield Shopping Centre, Penrith
Westfield Shopping Centre, East Gardens
Westfield Shopping Centre, Chatswood
Westfield Shopping Centre, Miranda
Westfield Shopping Centre, Parramatta
Westfields Sports High School
Westmead Railway Station
Westpac Banking Corporation, Sydney
Westpac Banking Corporation, Parramatta
Westpac Banking Corporation
NSW
NSW
$4,365
$1,060
NSW
NSW
NSW
NSW
NSW
NSW
NSW
NSW
NSW
NSW
WA
$1,084
$6,266
$1,420
$1,248
$3,117
$2,928
$1,868
$2,006
$6,221
$1,838
$2,055
}
St Paul’s Senior School
St Paul’s Primary School
St Peter Apostle Primary School
St Philip’s College – Griffiths House
St Spyridon College
St Ursula’s College
St Vincents & Mater Health Sydney
St Andrew’s Primary School
Standard Communications Pty Ltd
Star City Casino
Starkey Australia Pty Ltd
State Revenue Office
State Street Australia Limited
Stimson, Shirley J
Storch, Daniel
Strathfield Girls High School
Sule College Girls High School
Summer Hill Public School
Sunglass Hut Head Office
Sutherland District Trade Union Club
Swales, David
Sydney Boys High School
Sydney Grammar School St Ives
Preparatory
Sydney Ultrasound for Women
QLD
NSW
VIC
NT
NSW
NSW
NSW
VIC
NSW
NSW
NSW
VIC
NSW
NSW
NSW
NSW
NSW
NSW
NSW
NSW
VIC
NSW
$1,551
$1,730
$2,277
$1,330
$1,400
$3,430
$1,852
$1,214
$2,433
$8,000
$1,110
$1,691
$2,271
$1,200
$2,000
$1,340
$1,252
$1,521
$6,538
$1,362
$2,000
$2,468
NSW
NSW
$2,416
$4,635
Thomas, Fred G
Thomas & Coffey
Tintern Anglican Girls Grammar School
Titley, MG & EM
Toll Priority – DX Solutions
Toorak College
Toowoomba State High School
Tower Australia Limited
Toyota Financial Services
Toys R Us Store Support Office
Tranby College
Treasury of Craft
Trinity Grammar Preparatory School
Trivett Classic
Trivett Classic BMW
Trust Company Ltd
Trust Company of Australia Limited
Tully, Brooke
Tura Beach Country Club
NSW
NSW
VIC
NSW
NSW
VIC
QLD
NSW
NSW
NSW
WA
NSW
NSW
NSW
NSW
VIC
NSW
VIC
NSW
$1,000
$6,110
$1,359
$1,250
$1,384
$1,371
$2,563
$1,621
$29,770
$9,087
$1,888
$5,015
$1,878
$2,272
$6,800
$5,000
$5,500
$1,159
$1,230
Upper Coomera State College
Urangan State High School
Victoria Hotel
QLD
QLD
NT
$1,341
$1,007
$8,500
Westpac Matching Gifts Program
Winters, Katrina
Woolooware High School
Woolworths Limited
WorkCover QLD
Worroll, Shirley
Worsley, B
Wrighter, Edward M
Wynyard Park
Wyong Shire Council – Social Club
Yeatman, KA & OM
Young Presidents’ Organization
de Vries Tayeh
NSW
NSW
NSW
NSW
QLD
WA
NSW
NSW
NSW
NSW
NSW
SA
NSW
$16,206
$1,302
$2,160
$8,898
$2,907
$2,788
$2,750
$1,000
$5,610
$1,688
$2,250
$1,000
$2,110
{T
{U
V
{W
Y
and of course enormous thanks go to our Jeans
for Genes genies, thousands Australia wide :)
– C M R I
2 0 0 6 / 2 0 0 7
A N N U A L
R E P O R T – 4 3
How you can help
Children of the future will benefit from your support.
Call us now to help make a difference on freecall 1800 GENIES / 1800 436 437
Provide for the CMRI in your will – suggested form of wording:
‘I bequeath to the Children’s Medical Research Institute ABN 47 002 684 737 the sum of
$
free of all duties for the purposes of the said Institute and
the receipt of the Secretary or Treasurer of the Institute shall be sufficient discharge of the same.’
and/or make a donation now:
I/We wish to make a donation of
Payment is attached:
$
cheque
to the Institute.
money order
credit card
Card number
Expiry date
/
Name on card
Your name
Signature
Address
Postcode
Email
Telephone
Facsimile
Photocopy and fill out this coupon, and return it to us with your donation.
More information:
I would like the opportunity to discuss the work of the CMRI with a representative of the Institute.
Please send me more information on making a bequest.
Please put me on the mailing list to receive the CMRI’s quarterly newsletter, Under the Microscope.
Children’s Medical Research Institute ACN 002 684 737
Postal address:
Street address:
Telephone:
Facsimile:
Email:
Internet address:
4 4 – C M R I
2 0 0 6 / 2 0 0 7
Locked Bag 23 Wentworthville NSW 2145 Australia
214 Hawkesbury Road Westmead NSW 2145 Australia
02 9687 2800
Freecall: 1800 GENIES / 1800 436 437
02 9687 2120
info@cmri.com.au
www.cmri.com.au and www.jeans4genes.com.au
A N N U A L
R E P O R T –
Designed by The Glasshouse, Sydney
www.theglasshouse.com.au
hope
cmri.com.au 214 Hawkesbury Road Westmead NSW 2145 Australia